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Introduction

Behçet’s disease
Based on:
Managing Behçet’s Disease: an update on current and emerging treatment options
P.L.A. van Daele, MD, PhD, J.H. Kappen, MSc, P.M. van Hagen, MD, PhD, J.A.M. van Laar, MD, PhD
Ther Clin Risk Manag. 2009 Apr;5(2):385-90
“nieuwe ontwikkelingen in de Medische Immunologie 2010” Chapter 16 “Ziekte van Behçet” 
ISBN 978-90-73436-91-6
Jan AM van Laar, P. Martin van Hagen, Jasper H Kappen.
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InTrODuCTIOn
Behçet's disease (BD) is an multifactorial auto-inflammatory vasculitis characterized by 
recurrent oral -and genital ulcers, uveitis, and skin lesions [1, 2]. The first series of patients 
with BD was already published in 1937 as a triad of these symptoms [3]. Less frequently, 
involvement of the gastrointestinal tract, central nervous system and large vessels may 
occur. As in other immune mediated disorders BD is characterised by attacks rather than 
by a persistent inflammatory disease [4].
Cases of Behçet's disease cluster along the ancient Silk Road, which extends from east-
ern Asia to the Mediterranean basin. The reported prevalence in Turkey varies between 
70 and 420 per 100.000 [5]. In Northern European countries however the prevalence 
is probably less than 1 per 100.000 in Caucasians. It is believed that both genetic and 
environmental factors contribute to the development of the disease [6, 7]. Men might 
be more frequently and severely affected than women
Susceptibility to BD is strongly associated with the presence of the HLA-B51 allele 
and its presence is also strongly associated with a more aggressive course [8]. The cause 
of BD, however, is still unknown. Triggers such as infections, both viral and bacterial, 
trauma, and other stress factors may play a role.
Although the exact cause of BD remains to be elucidated, it is clear that neutrophils 
interacting with T-cells play an important role in the pathophysiology. The activated 
T-cells produce TNF-α, which in turn leads to production of other proinflammatory 
cytokines like interleukin 1 en interleukin 6 by other immune cells. These proinflamma-
tory cytokines stimulate migration and activation of leucocytes, thereby causing a local 
inflammatory response [2]. Additionally, a disturbed function of regulatory T-cell may 
also play a role. Eventually vessel -and subsequently tissue damage occurs, as can be 
seen in biopsies taken from BD lesions from various sites involved [4].
IMMune sysTeM en CyTOKInes
The inflammation in BD is characterized by a Th-1 and probably also Th-17 mediated 
immune response (figure 1) [2, 9]. In the early phase of inflammation granulocytes and 
gamma-delta T-cells (Tγδ) are identified in the affected tissues. These are believed to be 
activated by environmental "triggers" [10]. A lymfohistiocytic infiltrate is found in a later 
phase.
The assumption that granulocytes play an important role in BD is fed by a number of 
observations: increased prevalence of HLA-B51 in 13-80% of the patients [4] , associated 
with over-activated neutrophils. increased toll like receptor expressions on granulocytes 
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of BD patients, frequently occurring hyperactive granulocytes, and observations of 
hyperactive response of granulocytes to "heat shock proteins" and fragments of the 
bacterial cell wall [11]. The inflammatory effect of these observations seems that these 
hypersensitive granulocytes, but also Tγδ cells through antigen presenting dendritic 
cells start a cascade of pro-inflammatory cytokines. Several cytokines are involved in 
the pathophysiological mechanisms. IL6, produced by antigen presenting cells, which 
promotes the differentiation towards Th1 cells and IL23, produced by Tγδ cells that 
promotes the Th17 differentiation P40 [12, 13]. The central cytokine in this inflammatory 
process is tumor necrosis factor (TNF) -α, which is produced by virtually all the cells 
involved. TNF-α subsequently activates the production of other cytokines such as inter-
leukin (IL) -1β, IL-6, IL-8, IL-10 and IL-17 (Figure 1). Other inflammatory cells are attracted 
to the inflammation site and contribute to an inflammatory infiltrate. Increased tissue 
(pro) inflammatory cytokines and serum concentrations in various affected tissues from 
patients with BD are described [14-16]. Adisturbed , hyperactive local immune response 
seems responsible for the initial inflammatory symptoms that are seen in BD.
figure 1; Immunopathophysiology of Behçet’s disease. It is assumed that stimulation by pathogens of 
granulocytes, Tγδ and DCs, in a genetically predisposed host a cascade of inflammatory cytokines eventu-
ally lead to vascular damage and vasculitis.
Abbreviations: IL; interleukin, TNF; tumor necrosis factor, Tγδ; Tγδ subset T cells, Th; CD4 + cells Thelper, DC; 
dendritic cells
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Also regulatory T cells (Treg) are of interest in autoimmune diseases. These cells seem 
essential for the immunological homeostasis in which the T-cell-effector response is 
inhibited. The involvement of Treg in BD is debated. In summary, in BD tissue damage 
together with a local hyper-inflammation appears to play an important role.
GeneTICs
In patients of Turkish origin there is positive family history in 12% of the cases with a 
sibling risk ratio between 11–52 [2, 17]. The heritability of BD has been estimated to 
range between 20 to 60%, with the strongest genetic association embracing variants 
in HLA-B51, explaining about 20% of the disease heritability [2, 17]. The combination 
of epidemiological and genetic data suggest causal involvement of both genetic and 
environmental factors [6].
Over the years numerous single nucleotide polymorphisms (SNPs) have been found 
associated with BD [7, 18-20]. In 2010 the first genome-wide association study (GWAS) in 
BD cohorts of Turkish and Japanese origin demonstrated association of various variants 
in the known HLA-B51 domain, and two new association signals, mapping to the inter-
leukin-10 (IL10), and the IL-23 receptor–IL-12 receptor Beta2 (IL23R–IL12RB2) locus [21, 
22]. These associations later have been confirmed in an Iranian cohort [23]. Yet another 
study in Algerian individuals only replicated the associations from the IL10 variants [24]. 
GWAS in Chinese and Korean individuals reported associations of SNPs mapping to two 
other loci, with regions containing the signal transducer and activator of transcription 4 
(STAT4) and GTPase of immune associated protein GIMAP genes, respectively. Polymor-
phisms in IL10 and IL23R–IL12RB2 were not found to be significantly associated with BD 
in either of those studies [14,15]. Most recently associations with CCR1, STAT4 and KLRC4 
were identified by imputation analysis [25]. This study also identified the IL12A region 
as suggestively associated with BD, but genome wide significance was not reached. 
Discrepancies in association results, as have been shown for the GIMAP variants might 
be explained by the different ethnic origin of the cohorts studied [26, 27].
ClInICAl PICTure
Diagnosis:
Currently the diagnosis of BD is based on the criteria as proposed by the International 
Study Group for BD in 1990 [28]. To fulfil these criteria recurrent oral ulcers must be pres-
ent together with two or more of the following; recurrent genital ulceration, eye lesions, 
skin lesions or a positive pathergy test (table 1). This test consists of pricking a sterile 
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20G needle into the skin of a patient's forearm. The results are judged to be positive 
when the puncture causes an aseptic erythematous nodule or pustule that is more than 
2 mm in diameter at 24 to 48 hours. At the reaction site there is initially an accumulation 
of neutrophils, followed by the accumulation of mononuclear cells [29]. The pathergy 
test is sometimes considered pathognomonic for the disease but can also be positive in 
other diseases like pyoderma gangrenosum [30].
Clinical manifestations [2, 4] (Chapter 2):
Oral aphthous ulcers:
Often the oral ulcers are the first and sometimes the only symptom of the disease. An 
inverse relationship with cigarette smoking exists, in which a worsening of the disease 
is seen when stopping. The localization to the often very painful and persistent ulcers 
importantly affect the daily lives of patients, it can even lead to severe emaciation. Vari-
ous forms of ulcers are described; minor, major and herpetiform. The ulcers are aphtous 
in nature and can be up to 2 cm in diameter. They occur throughout the intestinal area 
and tend to form in places where a trauma, such as, for example, occurred after a dental 
procedure.
Genital ulcers:
Painful genital ulcers are described throughout the urogenital area. Such an ulcer is often 
mistaken for a sexually transmitted disease (STD). An STD must therefore be excluded 
before proceeding to treatment. The ulcers are characterized by poor wound healing, in 
more than 75 percent scar formation occurs.
Table 1: International Study Group criteria for Behçet’s disease
Finding Definition
Recurrent oral ulceration Minor aphthous, major aphthous, or herpetiform ulcers observed by the 
physician or patient, which have recurred at least three times over a 12 
month period
Recurrent genital ulceration Aphthous ulceration or scarring observed by the physician or patient
Eye lesions Anterior uveïtis, posterior uveïtis, or cells in the vitreous on slit-lamp 
examination; or retinal vasculitis detected by an ophthalmologist
Skin lesions Erythema nodosum observed by the physician or patient, pseudofolliculitis, 
or papulopustular lesions; or acneiform nodules observed by the physician 
in a post-adolescent patient who is not receiving corticosteroids
Positive pathergy test Test interpreted as positive by the physician at 24 to 48 hours
Behçet’s disease 15
Skin disorders:
Skin disorders are seen in 75 percent of the BD patients and again described in various 
forms. The most common skin lesions are sterile papulo-pustular lesions that may be 
found spread over the whole body. Erythema nodosum is not uncommon, often pres-
ent in female patients and usually seen on the lower extremities. Other common skin 
conditions are thrombophlebitis, pyodermal- or acnei-form abnormalities. Folliculitis 
and pustules often occur in places where skin shaved or minor skin damage can occur. 
'Nail-fold lesions' and dermatography are less frequently seen.
Pathergy skin test:
The pathergy skin test is a local inflammatory response to a sterile puncture and has a 
specificity of almost one hundred percent for BD. The sensitivity of the test varies consid-
erably and is between five and eighty percent. When using sterile needles the frequency 
of positive pathergy tests seem to be decreased.
Eye involvement:
Untreated eye symptoms can quickly lead to blindness. In non-Western countries twenty 
percent of the BD patients is blind. Each segment of the eye may be affected. Usually it 
involves inflammation in the anterior chamber (anterior uveitis). More seriously is pos-
terior uveitis in which the optic nerve may be involved. Scleritis and conjunctivitis have 
been reported in BD patients, but are not seen often [2].
Intestinal BD:
Because BD can also manifest in the small intestine and colon in the form of aphthous 
ulcers, intestinal scarring, fistula or perianal lesions, the possibility of confusion with 
Crohn's disease of is present. Microscopic, however, in BD granulomas are not often 
encountered. Granulomas are quite often are present in the Crohn's disease.
Joint involvement:
Non-erosive oligoarticular joint manifestationis often present. It usually remains restrict-
ed to the large joints such as the knee, ankle and wrist. Erosive defects are rarely seen.
Vasculitis:
Vasculitis plays a central role in the pathophysiological disease process and causes the 
involvement of various organs. Both veins and arteries can get involved at all levels, 
microvascular arterial vasculitis is seen the most. In addition, a wide variety of clinical 
syndromes, such as deep vein thrombosis, (pulmonary arterial) aneurysms, intra-ce-
rebral arterial occlusions, Budd-Chiari syndrome, and thrombophlebitis are described 
in BD-patients. All these disorders are caused by a local inflammation of the vascular 
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wall and therefore is treated as such with immunosuppressive medications. Pulmonary 
aneurysms caused by vasculitis may lead to life-threatening arteriobronchiale fistulas 
and and present late with hemoptysis.
Neurological manifestations:
Localization in the central nervous system is seen in 5 to 10 per cent of the cases and 
causes a high mortality rate. The brainstem is the most frequently affected, however also 
aseptic meningitis and arterial vasculitis is seen. The most common symptoms include 
cranial nerve dysfunction, ataxia, and bilateral pyramidal symptoms such as hemipa-
resis, areflexia or blatter dysfunction. Neuropsychiatric manifestations may manifest as 
behavioural changes, dementia and other psychiatric disorders. Polyneuropathy is not 
a symptom that is seen in BD. Diagnostics in neuro-BD is often very difficult because of 
the lack of hard diagnostic criteria. Examination of the CSF the total protein, neutrophil 
granulocytes and CSF pressure sometimes is slightly increased. However, a normal 
CSF examination does not rule out a cerebral BD. Various deviations can be seen ra-
diological. High intensive-enhancing parenchymal lesions are often only found using a 
T1-weighted MRI, whereas CT shows no abnormalities. A (MR) angiography may in some 
cases be used to demonstrate a cerebral vasculitis or vasculopathy. Cerebral vasculitis 
can be a rapidly progressive disease. A tight control is desired when a BD patient has 
striking migraine symptoms and loss of function.
CurrenT TreATMenT OPTIOns
First of all we must state that unfortunately most of the treatment regimens in BD the 
level of evidence is limited since there are few randomized controlled trials.
Treatment of patients with BD is directed by the presence of organ involvement, or 
vision –or life-threatening situations (table 2). Topical steroids are usually effective for 
mucocutaneous involvement. Some patients however respond insufficiently and in 
these cases additional treatment may be necessary. Colchicine is the mainstay of BD 
therapy, effective for refractory mucocutaneous disease, although a double blinded 
study conducted already in 1980 did not show a statistically significant reduction in the 
recurrence of both oral and genital ulcers as compared to placebo [31, 32]. Thalidomide 
has also been shown to be effective in patients with mucocutaneous lesions refractory 
to treatment with colchicine. Thalidomide exerts considerable side effects (neuropathy, 
constipation) and for obvious reasons should be avoided in women with childbearing 
potential unless they adhere to stringent anti-conceptive regime. Pentoxifylline, which 
reduces the production of inflammatory cytokines like TNF-α, was effective in reduc-
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ing the frequency and severity of oral an vaginal ulcers [33]. Alternative treatment for 
mucocutaneous involvement are dapsone [34] and cyclosporine. Cyclosporine is used 
infrequently for this indication for fear of side effects [35]. However, being a potent im-
munosuppressive agent, cyclosporine resulted in significantly more alleviation of oral 
aphthous ulcers versus colchicine in a study by Masuda et al. [36] Sulfasalazine is mainly 
effective in arthritis and gastrointestinal involvement [4, 37].
Involvement of internal organs, sight-threatening uveïtis, or severe CNS involvement 
may require much more aggressive treatment consisting of systemic corticosteroids of 
> 1mg/kg/day combined to DMARDs such azathioprine or cyclosporine. These immuno-
suppressives are considered effective treatment for patients with BD, especially those 
with uveitis. One of the newer immunosuppressive drugs, mycophenolic acid derivates, 
although not effective in mucocutaneous lesions [38] can be effective in therapy refrac-
tory gastro-intestinal involvement [39].
Table 2: Current treatment used for Behçet’s disease
Medication Dose Main indications
Prednisonev Local
Systemic: 0.5 – 1 mg/kg
Uveïtis
Mucocutaneous involvement
Induction treatment uveïtis
Neurological involvement
Refractory arthritis
Gastro-intestinal ulceration
Colchicine 0.5 - 1.5 mg / day Skin involvement
Arthritis
Dapsone 100 - 200 mg / day Mucocutaneous involvement
Arthritis
Azathioprine 2 - 3 mg / kg / day Uveitis
Pentoxifylline 1200 mg /day Mucocutaneous involvement
Sulfasalazine 1- 3 g / day Mucocutaneous involvement
arthritis
Thalidomide 50 - 200 mg / day Refractory mucocutaneous involvement
Cyclosporine 2 dd 3 - 5 mg/kg / day Uveïtis
Mucocutaneous involvement
Methotrexate 7.5 - 15 mg / week Arthritis
Uveitis (rarely)
Cyclophosphamide 750 mg / m2 /mo IV Life threatening involvement (vasculitis, 
neurological)
IFN-α-2a 9 million units 3 /week for 3 months 
followed by a low maintenance dose of 3 
million units 3 /week)
Uveitis
TNF-α blockers Various doses Uveitis
Arthritis
Gastro-intestinal ulceration
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Especially (large vessel) vasculitis involving the pulmonary arteries and neurological 
disease, both notoriously life-threatening call for intensive measures. In these cases the 
use of cyclophosphamide alone or in combination with prednisone is warranted [40, 41].
Interestingly, although the cause of BD is unknown, treatment with high dose penicil-
lin either alone or in combination with colchicine was effective in reducing symptoms 
(mucocutaneous and joint manifestations) in several studies. A possible role for strepto-
coccal infection has been proposed [42-44].
In some patients the aforementioned therapies are either ineffective or associated 
with intolerable adverse effects necessitating alternative treatment strategies. In the 
slipstream of the success of new developments in the management of immune medi-
ated diseases such as rheumatoid arthritis and IBD, promising designed novel agents 
targeting key-immunological factors of these immunopathological compatible diseases, 
have been tried in BD patients with sometimes astonishing results.
eMerGInG TreATMenT OPTIOns
As mentioned above, T-cells and cytokines are believed to play an important role in the 
pathogenesis of BD. Emerging therapies aim at influencing T-cell function or cytokines.
Interferon alpha
Interferon-α (IFN-α) maybe no longer deserves to be called an emerging therapy as it 
is used for therapy refractory BD for over twenty years [45]. IFN-α has been reported 
to restore the low natural killer cell activity in patients with BD to a near normal level. 
A double-blind study assigned 50 patients to receive either IFN-α2a (6 million units 3 
times weekly) or placebo for 3 months [46]. Significant decreases in pain and duration 
of oral ulcers, frequency of genital lesions, and number of pustular papules were noted 
in patients receiving IFN-α2a. The frequency and duration of erythema nodosum-like 
lesions and thrombophlebitis were also decreased in the same group. In a systematic 
review of 32 studies and 4 published abstracts published before 2002, a total of 338 
patients received either IFN-α2a or 2b of various doses [47]. Within a few months of 
therapy, eighty-six percent of the patients with mucocutaneous symptoms, 96% with 
arthritis, and 94% with uveitis exhibited a partial or complete response. Significant 
improvements were also found in erythema nodosum-like lesions, skin ulcerations, and 
superficial thrombophlebitis. Interferon-α-2a seems to be more efficacious than IFN-α-
2b. Compared with low-dose regimens, high-dose regimens were more effective and 
achieved more remissions. However, disease activity generally returned to baseline level 
either immediately after or up to 7 months after therapy was discontinued. Side effects 
of IFN-α include mild alopecia, mild leukopenia (generally reversible with discontinuing 
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interferon), influenza-like symptoms, and depression or psychosis. The recommended 
regimen is a high dose of IFN-α-2a (9 million units divided in 3 doses per week) for 3 
months followed by a low maintenance dose (3 million units divided in 3 doses per 
week). Since the successful advance of TNF blockers, IFN-α are seldomly used in the daily 
practice of most clinics, especially in the ErasmusMC.
Tnf-α blockers
It is believed that TNF-α plays a central role in the inflammatory process of BD.Th-1 proin-
flammatory cytokines such as IL-1-β, IFN-γ and IL-12, but most of all, TNF-α are involved 
in the inflammatory response that is held responsible for disease related symptoms. TNF 
blockers represent a novel regimen in the treatment of BD. The most often representa-
tive of this group is the chimeric TNF-α antibody infliximab. Its use has been reported 
effective in more than 10 smaller studies including a total of more than 120 patients and 
115 other single BD cases of refractory mucocutaneous lesions, severe gastrointestinal 
-or neurological involvement, and ocular disease [48-53]. Evidence. One of the most 
significant studies was published in 2004 by Sfikakis et al. [54] In this study 25 patients 
with ocular disease were treated with a single infusion of 5mg/kg infliximab. In all but 
one patient ocular inflammation was controlled within one day. In general, remarkable 
and swift improvement or complete resolution of the oro-genital ulcers, gastrointestinal 
ulcerations, and other BD related symptoms can be achieved shortly after one or two in-
fusions of infliximab at various doses ranging from 3 -10 mg/kg. A dose of 300 – 500 mg 
is generally accepted effective, but the time of interval and duration of therapy remain 
undetermined. In patients with acute, unilateral, posterior uveitis and significant reduc-
tion of visual acuity (<0.2), as well as in those cases with inflammation of the macular 
area, a single infusion of infliximab, or intravitreal steroids, may be superior to other 
immunosuppressive drugs. In cases of bilateral posterior eye segment inflammation, a 
single infusion of infliximab could be used as a first-line agent to achieve a fast-onset 
response, along with the initiation of other immunosuppressive drugs. However, if the 
ocular disease remains uncontrolled a combination of immunosuppressive regimens 
with repetitive infusions of infliximab 5 mg/kg every 6–8 weeks for up to 2 years can be 
initiated.
Another TNF-α blocker used in BD is the fusion protein etanercept. One double-
blind, placebo-controlled study has been conducted by Melikoglu et al. [55] This study 
involved 40 male patients with mainly mucocutaneous disease randomly given either 
4 weeks of 25 mg etanercept (subcutaneously twice a week) or placebo. Significant 
improvements of oral ulcers, nodular and papulopustular lesions were observed in the 
etanercept group. Within four weeks 45% of the etanercept group remained free of oral 
ulcers compared with only 5% in the placebo group. No significant improvement in 
genital ulcers or pathergy positivity was observed. Eighty-five percent of the patients 
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receiving etanercept were free of nodular lesions compared with 25% of those in the 
placebo group. Most patients experienced recurrent disease 3 months after etanercept 
was stopped. Other case reports include in total less than 10 BD patients mainly success-
ful treated with etanercept.
In 2006 two groups reported treatment with adalimumab, a human TNF-α antibody, 
in 9 refractory BD patients. In both retrospective studies all patients various symptoms 
resolved swiftly and persistently [56, 57]. Adalumimab could be given for at least 3 
years without serious adverse effects. In Chapter 4 we present new data on the use of 
adalumimab in BD patients.
The role of TNF blockers in patients with uveitis is currently accepted for selected cases. 
Although reportedly very effective in BD, the place of TNF-α blockers in the therapeutic 
strategy, its long-term effects and the timing of intervals still has not been determined 
yet.
Anti Il-1 and anti Il-6
The role of other cytokines like IL-1 and IL-6 in the pathogenesis of BD is becoming more 
eminent. Blocking the involved pathways can lead to new treatment options in BD. A 
case report of 2008 already describes a patient with refractory BD responding rapidly 
to treatment with daily anti IL-1. Lowering the dose to alternate day injections led to an 
increase in disease activity, again responding to an increase in the dose [58]. A recent 
overview of biological treatment in BD shows positive effects with no new safety is-
sues [59]. Also nhibition of IL-6 signalling could be promising [59, 60]. Tocilizumab is a 
humanized monoclonal antibody that binds both to soluble and to membrane-bound 
IL-6 receptor and has been shown to be effective in rheumatoid arthritis. It goes without 
saying that more data, on efficacy and indication with regard to these novel treatment 
modalities is needed.
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“Although the etiology of Behçet’s disease (BD) still needs to be unravelled, it is widely 
considered an excessive T-cell mediated inflammatory response in a genetically suscep-
tible host.” This sentence is often the introduction in research articles on BD. It sum-
marises not only the reason for this thesis but also covers the outline.
The chapters in this thesis travel from the demography towards morbidity towards 
immunopathology and etiology ending with (molecular designed) therapy in BD.
Chapter 2 will focus on the epidemiology of BD in the Rotterdam area. Apart from an 
overview of patients characteristics and with prevalence data of the different ethnicities, 
we take place in the camp that challenges, the assumption that the prevalence of BD 
declines after immigration. In Chapter 3 genetic aspects of BD are presented, starting 
with a targeted gene approach, the prevalence of NOD variants that are related to 
Crohn’s disease, a disorder with many similarities to BD. Subsequently a non-targeted 
approaches by use of a Genome wide associations study as well as a whole genome 
sequence is presented. Chapter 4 cytokines addresses the subject of involved, cytokines 
and where to measure these, in tissue or in serum? As a result of the immunopathologi-
cal studies, novel treatment modalities are shown in Chapter 5, with emphasis on the 
use of biologicals such as the major cytokine (TNF) blocking agents . Finally the results 
are summarized and discussed in chapter 6.
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ABsTrACT
Objectives: It has been shown previously that three NOD2 variants (Arg702Trp, Gly908Arg 
and Lue1007fs) are associated with Crohn’s disease (CD), a disorder clinically resembling 
Behçet’s disease (BD). We studied the frequency of these variants in BD patients.
Methods: DNA samples of 200 BD patients (59 Western Caucasian, 139 Middle Eastern of 
Arab descent (ME) and 2 Asian) and 520 healthy controls (444 Western Caucasian and 76 
ME) were genotyped using a Taqman assay.
Results: Both the Arg702Trp and Leu1007fs (=frameshift) variants were significantly less 
frequently present amongst BD patients compared to healthy controls (0.5% versus 
5.8%, p<1.10-5 and 0.0% versus 1.8%, p<0.007, respectively). In the Western Caucasian 
subpopulation Arg702Trp was significantly less frequent in the BD group as compared 
to the controls (p = 0.04). In the ME subpopulation a trend was observed (p<0.06).
Conclusion: Of the three CD associated SNPs one of the variant NOD2 alleles was signifi-
cantly less present in Western Caucasian BD patients.
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InTrODuCTIOn
BD is an idiopathic systemic vasculitis characterized by recurrent oral and genital aph-
thous ulcers, skin lesions, ocular inflammation and more seldomly, arthritis, CNS -and 
gastrointestinal tract inflammation [1, 2].
Prevalence varies from 110 to 420 per 100.000 in Turkey to about 2 per 100.000 in 
western countries [2]. A strong association with HLA-B51, a positive family history in 
12% of non-Caucasoid patients and a sibling risk ratio of 11-52 suggest causal involve-
ment of both genetic and environmental factors [3].
The etiology of BD is still to be unravelled but it is widely considered an excessive 
inflammatory response, possibly triggered by an (infectious) antigen in a genetically 
susceptible host. The abundance of neutrophils in early lesions and the association of 
HLA-B51 with neutrophil activation indicate involvement of innate immunity in BD 
[1-2, 4].
Similar symptoms such as uveitis, arthritis, erythema nodosum and colitis with 
ileocaecal mucosal inflammation and punched-out fissuring ulcers suggest a genetic 
overlap between BD and CD [5, 6]. Recently, the latter has been linked with genetic al-
terations in innate immunity. Increased susceptibility to CD is associated with two SNPs 
(Arg702Trp, Gly908Arg) and a frameshift mutation (Leu1007fs) in the CARD15 gene [7, 
8]. This gene encodes for the nucleotide-binding oligomerization domain containing 2 
(NOD2) protein. In short, NOD2 acts by recognition of muramyl dipeptide (MDP) derived 
from peptidoglycan, present in the cell wall of all bacteria. NOD2 engagement activates 
nuclear factor-kappaB (NF-кB), a transcription factor with a central role in both innate 
and adaptive immunity. This transcription factor is also considered to play a key role in 
many inflammatory diseases including BD and CD[7,9,10].
Since BD and CD share many clinical features and for both diseases innate immune 
mechanisms appear crucial, we addressed the hypothesis that NOD2 variants are 
mechanistically operational in both diseases. We therefore determined the occurrence 
of the aforementioned NOD2 SNPs in two large and independent BD cohorts
MATerIAls AnD MeTHODs
study population
Two cohorts of in total 200 unrelated BD patients (52 from the Erasmus MC at Rotter-
dam, 109 from The Jordan Hospital, Amman, Jordan and St John’s Ophthalmic Hospital, 
East Jerusalem, Israel and 39 from St. Thomas’ Hospital, London, UK). Of those, 59 were 
Western Caucasian, 2 of Asian and 139 from ME origin of Arab descent. All patients 
fulfilled the International Study Group criteria for the diagnosis of BD[5]. In total 520 
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healthy controls were recruited (444 Caucasian and 77 ME). Dutch controls were healthy 
Caucasian blood donors, the UK controls were Caucasian transplant donors from which 
Afro-Caribbean and Far Eastern individuals were removed. Given the high prevalence 
of BD in the ME, local controls were either hospital staff or otherwise healthy cataract 
patients matched to the same population as BD patients from each country. ME controls 
were over 50 years of age as new presentation with BD after this age is extremely unusual 
in this population. The ethical committees of all centers approved genetic evaluations 
after written informed consent by the patients.
Genotyping
Genomic DNA was extracted from 5 mL samples of peripheral venous blood using the 
magnetic bead separation technique from AGOWA (Berlin, Germany) on a Microlab 
STAR pipetting robot (Hamilton Robotics, Reno, Nevada, USA). 1–2 ng genomic DNA 
was dispensed into 384-well plates using a Caliper Sciclone ALH3000 pipetting robot 
(Caliper LS, Mountain View, Ca, USA). Genotypes were determined using a Taqman allelic 
discrimination assay. The Assay-on-Demand service (www.appliedbiosystems.com) was 
used for the polymorphisms Arg702Trp and Gly908Arg. For Leu1007fs the Primers and 
probes for Leu1007fs were designed as described by Inhora et al.[8] (Isogen, IJsselstein, 
The Netherlands).
The PCR reaction mixture for the assay-on-demand assays included 1–2 ng of genomic 
DNA in a 2 μL volume and the following reagents: FAM and VIC probes (200 nM), primers 
(0.9 μM), and 2x Taqman PCR master mix (ABgene, Epsom, UK). For Leu1007fs the CPR 
reaction mixture included 2 ng of DNA in a 2uL volume and the following reagents: FAM 
probes (250 nM, TET probe (500 nM), primers (300 nM) and 2x Taqman PCR master mix 
(Applied Biosystems Inc, Foster City, Ca, USA). PCR cycling reaction was performed in 
384-well PCR plates in an ABI 9700 PCR system (Applied Biosystems Inc) and consisted of 
initial denaturation for 15 min at 95 °C, and 40 cycles with denaturation of 15 s at 95 °C 
and annealing and extension for 60 s at 60 °C. Results were analyzed by the ABI Taqman 
7900HT using the sequence detection system 2.22 software (Applied Biosystems Inc).
statistics
All data were submitted for Hardy Weinberg Equilibrium (HWE) calculations before 
inclusion in the analyses. Subjects were grouped according to genotype for the poly-
morphisms of interest. Per subject the allele information of both alleles was added. To 
detect allele frequency differences between cases and controls Pearson’s chi-square 
test was used. The analyses were performed in Haploview 4.0. A p-value of < 0.05 was 
considered significant.
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resulTs
Of all alleles less than 2.5% were excluded for further data processing because genotyp-
ing failed. In the 200 patients (400 alleles) and 520 controls (1040 alleles) no homozygous 
variants were present.
Both the Arg702Trp and Leu1007fs variants were significantly less frequently present 
among BD patients compared to healthy controls. The largest difference was found 
in the Arg702Trp variant: 0.5% versus 5.8%. For the Leu1007fs variant a difference of 
0.0% versus 1.8% was observed. The frequency of the NOD2 Gly908Arg variant was not 
significantly different between the BD patients and the controls (Table 1).
Differences in frequencies of NOD2 polymorphisms may vary with geographical loca-
tion [11]. We thus separately re-assessed the SNPs of the Western Caucasian and Middle 
Eastern subpopulations. Though not powered for this analysis, the Arg702Trp variant 
remained significantly reduced in the Western Caucasian subpopulation (p=0.042). In 
the ME group a trend (p=0.058) was seen for a reduced occurrence of Arg702Trp. The 
Leu1007fs variant was not significantly different in the sub-cohorts (Table 1).
DIsCussIOn
In this genetic study consisting of 200 BD patients, three NOD2 variants were genotyped 
to test the assumption that these variants have a similar distribution as in CD patients. 
Contrary to this initial hypothesis, we observed a significantly lower frequency of two of 
the three variant alleles in the BD group as compared to healthy controls.
In the subgroup analysis, a statistically significant difference was obtained for the 
Arg702Trp variant allele of the Caucasian subpopulation. Our study was appropriately 
powered to identify frequencies of NOD2 variants in the same magnitude as described 
for CD. In contrast to this we observed a lower proportion of variant alleles in our BD 
population. Apparently the other subgroups in our study were too low in number to 
reach significance.
In our study we focused on individual SNP frequencies in an ethnically mixed cohort 
and extracted subpopulations. Ahmad et al. described haplotypes of three NOD2 variants 
in combination with other SNPs in 374 patients and 500 controls and could not find an 
association with BD[11]. Details on the individual variants, however, were not presented. 
Uyar et al used an entirely Turkish cohort (existing of 85 BD patients and 100 healthy 
controls) and could not demonstrate a significant difference[12]. It has been shown in 
other studies as well as in our present study that the NOD2 variants are observed at a 
lower frequency in ME cohorts[11, 12, 13]. Therefore, the size of the Turkish cohort might 
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be too small to detect the observations made in our larger study. A relation of NOD2 
variants and HLA-B51 has not been shown in the past and therefore not expected to be 
of value in the present study since these genes are located on different chromosomes 
(16 and 6, respectively) [11, 12].
Assuming that the findings in the current study can be confirmed by future studies, 
it is of interest to speculate how the low frequency of NOD2 variants in BD might con-
tribute to the understanding of the underlying mechanism of the disease. It is clear that 
variation in many genes will contribute to BD susceptibility and disease progression. 
Candidates are the PTPN22 620W, IL-10 and TNF-α genes that support an increased 
inflammatory responses and a failure of regulation[14]. Similar mechanisms in CD are 
postulated to explain the involvement of NOD2 variants leading to decreased NF-кB 
activation (loss of function) and thus reduced defensin production resulting in an in-
creased bacterial load in the gut of CD patients[9, 15, 16]. Moreover, NOD2 activation 
inhibits stimulation of Toll-like receptors by pathogen products, and as NOD2 function 
is impaired, TLR signalling is enhanced and generates an exaggerated inflammatory 
response inducing tissue damage[9, 15].
In a second model transgenic expression of the Leu1007fs variant show a gain of func-
tion, with a direct increase in NF-кB, proinflammatory cytokines and tissue damage[9]. 
A potential connection between these paradoxical results is the kinetics of the NOD2 
response. Acute stimulation of human blood-derived macrophages with the NOD2 
agonist, muramyl dipeptide (MDP) induces a proinflammatory cytokine response. By 
comparison, persistent treatment of cells with MDP prior to activation through TLR2 or 
TLR4 ligands decreases cytokine responses, possibly through induction of IRAK-M, in 
support of control of TLR signalling. However, this tolerance is lost in cells from Leu1007fs 
homozygous patients[17]. As gut epithelial cells, dendritic cells and macrophages are 
in constant contact with bacterial products of the normal gut flora it is proposed that 
such tolerance is a protective mechanism[18]. Failure to control responses would lead to 
tissue damage as seen in CD.
Our findings suggest that NOD2 variants react in some cases with a decreased 
production of inflammatory cytokines to an exogenous stimulus. This is supported 
by the observation that NOD2 gene-deficient mice show reduced joint inflamma-
tion and are protected against early cartilage damage after intraarticular injection of 
Streptococcus pyogenes cell wall fragments[19]. In addition to this, human peripheral 
blood mononuclear cells of Leu1007fs variant donors exposed to cell wall fragments, 
produce less TNF-α and IL-1β than healthy controls[19]. However, this is contradictory 
to macrophage data discussed above, and may be due to the in vivo nature of these 
experiments, route of challenge, or the type of antigen used. The complex role of NOD2 
in response to bacterial challenge in different cell types should be addressed in BD and 
other conditions.
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In conclusion, our observations indicate that at least Western Caucasian carriers of the 
NOD2 variant allele have a reduced risk of developing BD. Our study contributes to the 
general assumption that genetic factors are involved in BD. It will therefore be of consid-
erable interest to investigate other variants in BD patients in order to gain more insight 
into the pathophysiology and potentially identify new leads for treatment options.
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ABsTrACT
Introduction: The etiology of Behçet’s disease (BD) is unknown, but widely considered 
an excessive T-cell mediated inflammatory response in a genetically susceptible host. 
Recent genome-wide association studies (GWAS) have shown limited number of novel 
loci-associations. The rarity and unequal distribution of the disease prevalence amongst 
different ethnic backgrounds have hampered the use of GWAS in cohorts of mixed 
ethnicity and sufficient sample size. However, novel statistical approaches have now 
enabled GWAS in admixed cohorts.
Methods: We ran a GWAS on 336 BD cases and 5,843 controls. The cases consisted of 
Western Europeans, Middle Eastern and Turkish individuals. Participants from the Gen-
eration R study, a multiethnic birth cohort in Rotterdam, The Netherlands were used as 
controls. All samples were genotyped and data was combined. Linear regression models 
were corrected for population stratification using Genomic Principal Components and 
Linear Mixed Modelling. Meta-analysis was performed on selected results previously 
published.
Results: We identified SNPs associated at genome-wide significant level mapping to 
the 6p21.33 (HLA) region. In addition to this known signal two potential novel associa-
tions on chromosomes 6 and 18 were identified, yet with low minor allele frequencies. 
Extended meta-analysis reveal a GWS association with the IL12A variant rs17810546 on 
chromosome 3.
Discussion: We demonstrate that new statistical techniques enable GWAS analyses in a 
limited sized cohort of mixed ethnicity. After implementation, we confirmed the central 
role of the HLA region in the disease and identified new regions of interest. Moreover, 
we validated the association of a variant in the IL2A gene by meta-analysis with previ-
ous work. These findings enhance our knowledge of genetic associations and BD, and 
provide further justification for pursuing collective initiatives in genetic studies given 
the low prevalence of this and other rare diseases.
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InTrODuCTIOn
Behçet’s disease (BD) is a systemic auto-inflammatory occlusive vasculitis presenting 
with oral and genital aphthous ulcers, skin lesions, ocular inflammation and a pathogno-
monic pathergy test [1-3]. Although the etiology of the disease is largely unknown, it is 
considered to be an excessive inflammatory response possibly triggered by an infectious 
antigen in a genetically susceptible host. Prevalence varies from 110–420 per 100,000 in 
the Middle East (Turkey) to about 2 per 100,000 in Western countries [3, 4]. In patients of 
Turkish origin there is a positive family history in 12% of the cases with a sibling risk ratio 
between 11–52 [3, 4]. The heritability of BD has been estimated to range between 20 to 
60%, with the strongest genetic association embracing variants in HLA-B51, explaining 
about 20% of the disease heritability [3, 4]. The combination of epidemiological and 
genetic data suggest causal involvement of both genetic and environmental factors [5].
Over the years, numerous single nucleotide polymorphisms (SNPs) have been found 
associated with BD [6-9]. In 2010 the first genome-wide association study (GWAS) in BD 
cohorts of Turkish and Japanese origin demonstrated association of various variants in 
the known HLA-B51 domain, and two new association signals, mapping to the interleu-
kin-10 (IL10), and the IL-23 receptor–IL-12 receptor Beta2 (IL23R–IL12RB2) locus [10, 11]. 
These associations later have been confirmed in an Iranian cohort [12]. Yet another study 
in Algerian individuals only replicated the associations from the IL10 variants [13]. GWAS 
in Chinese and Korean individuals reported associations of SNPs mapping to two other 
loci, with regions containing the signal transducer and activator of transcription 4 (STAT4) 
and GTPase of immune associated protein GIMAP genes, respectively. Polymorphisms in 
IL10 and IL23R–IL12RB2 were not found to be significantly associated with BD in neither 
of those studies [14,15]. More recently, associations with CCR1, STAT4 and KLRC4 were 
identified by means of imputation and GWAS meta-analysis [14]. This study also identified 
the IL12A region as suggestively associated with BD, but genome wide significance (GWS) 
was not reached. Discrepant association results, as those observed for variants mapping 
to the GIMAP locus, might be explained by the different ethnic origin of the cohorts stud-
ied [15, 16]. Therefore, studying cohorts of diverse ethnic background may be useful to 
understand the origin of these differences. Moreover, the inclusion of multiple ethnicities 
results in larger datasets (representing higher power) crucial for these analyses given the 
typically small effects of common genetic variants discovered by the GWAS approach [17]. 
Nonetheless, GWAS results can be confounded by ancestry differences between cases and 
controls, potentially leading to spurious associations. This challenge in multi-ethnic stud-
ies has so far been approached by methods that take into account confounding by genetic 
ancestry, such as correction for Genomic Principal Components (GPC) [18]. More recently, 
linear mixed models (LMM) have been introduced as a reliable method to correct not only 
for ancestry differences, but also for family structure and/or cryptic relationships [19].
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We have therefore set up a multi-center GWAS including BD patients of both Middle 
Eastern and Western background. We demonstrate that by means of novel statistic ap-
proaches it is feasible to run a GWAS in a small multiethnic cohort and use these results 
for meta-analysis.
MATerIAls AnD MeTHODs
study populations
A total of 369 unrelated BD patients from 18 different geographic origins were included 
in our study (Table 1).
The age range was 18 to 73 years (mean 47 years). All patients fulfilled the Interna-
tional Study Group (ISG) criteria of BD diagnoses [20]. No exclusion criteria were applied.
Table 1. Cases before and after QC. Collection at [1] Erasmus MC at Rotterdam, The Netherlands, [2] Uni-
versity Hospital of Cukurova, Turkey, [3] St John's Ophthalmic Hospital, Jerusalem, Israel, [4] St Thomas’ Hos-
pital, London, UK, [5] University Hospital, Damascus, Syria, Ethnicity of cases after QC.
ethnicity number of patients Collection number of patients after QC
Afghanistan 1 [1] 1
Iranian 4 [1] 4
Lebanese 1 [1] 1
Cape Verde 2 [1] 2
Curacao 1 [1] 1
Dominican Republic 1 [1] 1
Dutch caucasian 24 [1] 20
Greece 1 [1] 1
Israel 1 [1] 1
Jordan 1 [1] 1
Morocco 16 [1] 12
Surinam 2 [1] 1
Thailand 1 [1] 1
China 1 [1] 1
Turkey 35 [1] 32
Turkey 91 [2] 87
Arab Jerusalem ancestry 110 [3] 98
UK caucasian 38 [4] 33
Syrian 38 [5] 38
Total 369 336
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As controls, 87 Syrian healthy volunteers (22-73 years, mean 51 years) and 5,756 
participants from the Generation R study, a multi-ethnic birth cohort in Rotterdam (4-9 
years, mean 6 years), The Netherlands , were used [21].
Replication was pursued in a cohort of 82 BD patients who met the ISG criteria, and 
98 ethnically matched controls in Western European, collected from Birmingham and 
Midland Eye Centre, Birmingham, UK.
The ethics committees of the involved centers (Erasmus MC (METC), Ethical Com-
mitte at Çukurova University and Sandwell and West Birmingham Hospitals Trust Ethics 
Committee) approved the study, and written informed consent was obtained from all 
participants.
Genome wide genotyping
Genotyping of cases and controls (including the Generation R Study) was performed 
using the Illumina HumanHap 610K and/or 660 K arrays, following manufacturers proto-
cols. Quality Control (QC) was performed individually for each set following a standard 
protocol to exclude samples and SNPs with low quality genotyping. Markers with minor 
allele frequency (MAF) ≤ 1%, missing genotypes ≥5% or which failed an exact test of 
Hardy-Weinberg equilibrium proportions in the controls (P<1x10-7) were excluded from 
the datasets. Samples with gender discrepancy, excess of heterozygosity, duplicates or 
samples with relatedness or other inconsistencies were also removed. In a subsequent 
stage, we extracted SNPs common to both platforms which passed individual QC and 
then applied the QC protocol for the combined dataset.
Phenotype-Genotype Analyses
Heritability
To characterize the extent to which common genetic variants play a role in BD suscep-
tibility, we applied a recently proposed approach for estimating heritability based on 
genome-wide sharing between distantly related individuals, as implemented in the 
GCTA software in combination with the determination of ancestry-aware kinship coef-
ficients by REAP software [22, 23] . No pairs exceeded the standard cutoff coefficient of 
0.025 for genetic relatedness, confirming that no two individuals in the analysis were 
closer than third degree cousins. Relatedness coefficients calculated from REAP were 
used in the relatedness matrix before implementing GCTA. A disease prevalence of 
0.42% was used in the modelling [3, 4].
Genome-wide association analysis
Association between BD susceptibility and 553.224 genome-wide SNPs was carried out 
using a regression framework adjusting for population stratification. GWS threshold for 
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the association was established at p<5x10−8. Two different strategies were followed to 
adjust for population sub-structure in the data.
Genomic Principal Components
In the first approach, 20 GPC were obtained for all pairs of individuals in the combined 
dataset based on the similarities of individual genotypic profiles for 37,060 independent 
autosomal SNPs contained in the HapMap Phase II release 22 build 36 [24] using Multi-
Dimensional Scaling (MDS) as implemented in PLINK (http://pngu.mgh.harvard.edu/
purcell/plink/). Afterwards, we performed logistic regression adjusting for those 20 GPC.
Linear Mixed models
In the second approach we used LMM in order to account for possible population 
structure in the association analysis. This methodology estimates the level of related-
ness even between independent individuals using the genotyped markers. By modeling 
the dissimilarity between genotypes of the subjects, it is able to correct the association 
results for stratification. This approach is implemented in the publicly available EMMA 
eXpedited (EMMAX) software [25]. Since the effect sizes reported by EMMAX are based 
on Mantel–Haenszel statistics, the odd ratios for associations of the significant SNPs 
were estimated from the regular logistic regression models performed in PLINK.
Meta-analysis
Meta-analysis of our own study results with published results for the BD suggestive 
associated SNP rs17810546 [14] was performed using an inverse variance fixed-effects 
approach in METAL [26]
replication analysis
Four SNPs: rs8187722, rs439033, rs11969661 and rs17087141 were genotyped using 
TaqMan assays designed by Applied Biosystems, Warrington, UK in 82 BD patients and 
98 control samples. In short, PCR was performed in 384-well plates with a 10 µl total 
reaction volume containing 20 pg/ml DNA (samples) or water (controls) and 2x LC-480 
probe master (Roche, West Sussex UK) followed by endpoint genotyping analysis us-
ing the LC-480 system (Roche, West Sussex UK). Genotypes were determined as either 
homozygous (e.g. AA or GG) or heterozygous (e.g. AG) according to the presence or 
absence of fluorescence for each genotype.
Genome-wide association study in an admixed case series reveals IL12A as a new candidate in Behçet disease 61
resulTs
An overview of the ethnicity of the included BD cases is presented in Table 1; all controls 
were collected in St John's Ophthalmic Hospital, Jerusalem and had Arab ancestry. In 
order to gain power and match all remaining ethnicities, this dataset was combined with 
the genotyped samples from the multiethnic Generation R Study.
Genome wide Genotyping
Genotyping was performed in 456 samples (369 cases and 87 controls) collected from 
the different participating hospitals (Erasmus MC at Rotterdam, The Netherlands, 
University Hospital of Cukurova, Turkey, St John's Ophthalmic Hospital, Jerusalem, 
Israel and by St Thomas’ Hospital, London, UK). After quality control, 553,224 genotyped 
SNPs in 423 of these samples remained. We excluded 33 patients (including 1 control) 
because of low Illumina call rate (< 97.5%) and one more individual was excluded for 
gender mismatch. After QC of this combined dataset, 336 cases and 5843 controls were 
available for analysis.
Phenotype Genotype Analyses
Heritability
The heritability estimate, based on the 505,454 genotyped SNPs and 4,855 unrelated 
individuals (296 cases) was 32.0% (95%CI 21.0-44.0%;P= 5.5E-17). Thus a considerable 
percent of the BD risk is explained by the additive effect of the common SNPs analyzed.
Genomic Principal Components
The representation of the first GPC for the combined dataset projected together with 
the three reference panels of the International HapMap Project Phase II known as YRI, 
CEU and CHB/JPT representing populations of African, European and Asian background 
respectively [27] is shown in Figure 1. As shown by the overlapping distribution across 
the four first GPC, BD cases (represented in black) are well matched by genetic ancestry 
to controls (represented in yellow Syrian volunteers and grey for Generation R partici-
pants).
Genome wide association analysis
Association analyses were performed for 505,454 SNPs. As expected in such structured 
population, results from analysis without any type of stratification adjustment, showed 
association through the whole genome and a Genomic Inflation Factor (λ) of 5.25 (Sup-
plementary Figure 1). After GPC correction, the association analysis showed minimal 
inflation of the test statistics with a λ of 1.035 (Figure 2).
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The top associated SNPs mapped to the HLA region on chromosome 6 with rs7770216 
being the most significant (Table 2). Yet, another GWS signal in chromosome 18 driven by 
rs17087141 mapped to a region containing the uncharacterized miscRNA LOC400655.
Additional association analyses using different strategies including reduction of num-
ber of matching controls (to different case/control ratios) and incorporating different 
number of genomic principal components in the models yielded similar results for effect 
coefficients and genomic inflation factors (data not shown).
GPC1 GPC1 GPC1
GP
C2
GP
C3
GP
C4
figure 1. Genetic substructure of the Combined GwAs dataset. Two-dimensional scatterplots from 
multidimensional scaling analyses of the Generation R Study and Behçet collected data together with the 
three initial Panels form the HapMap Project. Each dot represents an individual in the dataset. Color codes: 
Grey=Generation R, Black= Behcet Cases, Yellow = Jordan controls. Blue= CEU, Red=YRB, Green= JPT.
figure 2. Behçet GwAs results using Genomic Principal Components (GPC) adjustment. Each dot rep-
resents an SNP in the dataset. a. QQ-plot. Associated SNPs deviating from the null hypothesis of no associa-
tion (identity line). b. Manhattan plot. SNPs showing association with the disease map to chromosome 6 
and a singleton in chromosome 18.
Genome-wide association study in an admixed case series reveals IL12A as a new candidate in Behçet disease 63
Results from the GWAS analysis using EMMAX yielded three independent GWS signals 
(Table 2). In addition to those mapping to the two previously described BD loci from 
chromosomes 6 and 18, an additional signal was found on chromosome 6q25.3 6 in 
the solute carrier family 22 member 3 (SLC22A3) gene region. The three most significant 
markers underlying this GWAS signal included rs11969661, rs439033 and rs8187722 
(Table 2). Using EMMAX resulted in adequate adjustment for population stratification as 
corroborated by λ=1.0 (Table 2) and the absence of early deviation from the identity line 
in the QQplot (Figure 3).
The most significant SNP identified by the EMMAX approach maps also to the HLA 
region in chromosome 6. The regional association plot of this HLA-B region is shown in 
Supplementary Figure 2. This HLA-B region has been associated with BD susceptibility 
in previous GWAS analyses [10, 22]. Figures 4 and 5 show the association plots for the 
Table 2. Gws snPs associated with Behçet’s disease susceptibility using GPC and eMMAX approach-
es. Results for the association analysis when correcting for 20 PCs to adjust for stratification. In italic font the 
SNPs which show association only by one of the two approaches
CHr snP BP A1 A2 MAf n 20PCs eMMAX*
Or P P
6 rs9380215 31157634 A G 0.09 6178 2.132 1.32E-10 3.15E-15
6 rs4947296 31166157 C T 0.09 6178 2.131 1.38E-10 4.98E-15
6 rs9263509 31174398 T C 0.16 6179 1.82 6.62E-09 2.69E-10
6 rs2233984 31187243 A G 0.09 6179 2.064 3.35E-10 1.08E-15
6 rs4495304 31188697 C T 0.09 6028 2.069 7.92E-10 3.84E-14
6 rs4959053 31207556 A G 0.09 6175 2.348 1.20E-12 3.90E-17
6 rs2523589 31435313 C A 0.43 6177 0.5466 2.92E-09 5.83E-08
6 rs2844575 31442924 G A 0.48 6173 1.81 5.62E-10 5.92E-08
6 rs9266409 31444547 C T 0.25 6178 2.183 3.66E-16 2.62E-18
6 rs2253907 31444849 A G 0.48 6175 1.797 4.41E-10 1.46E-09
6 rs7770216 31448590 T G 0.26 6072 2.198 9.75E-17 2.25E-18
6 rs6933050 31451611 C T 0.25 6178 2.183 3.69E-16 2.59E-18
6 rs1131896 31487094 A G 0.31 6141 1.647 6.86E-08 2.66E-09
6 rs2256028 31487177 T G 0.21 6177 1.784 1.72E-09 7.49E-12
6 rs2848713 31492458 A G 0.1 6173 2.118 3.03E-12 7.08E-22
6 rs11969661 160626409 T C 0.02 6179 2.696 1.30E-03 5.15E-09
6 rs439033 160739406 C T 0.02 6163 2.016 2.30E-03 1.14E-08
6 rs8187722 160784748 G A 0.01 6179 1.696 1.00E-04 2.87E-15
18 rs17087141 69036707 C T 0.03 6167 4.925 1.08E-13 2.81E-18
* Odd ratios cannot be calculated by EMMAX approach
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figure 3. Behcet GwAs results using linear Mixed Models Genomic approach. Each dot represents 
an SNP in the dataset. a. QQ-plot. Associated SNPs deviating from the null hypothesis of no association 
(identity line). b. Manhattan plot. SNPs showing association with the disease map to two different signals 
in chromosome 6 and a singleton in chromosome 18.
rs8187722
figure 4. snP association plot for Behçet’s susceptibility-associated region of chromosome 6q25.3. 
Dots represent GWAS P-values (EMMAX approach) and positions of SNPs found within the 6q25.3 locus. The 
top SNP, i.e. rs8187722, is denoted by a diamond. Different colours indicate varying degrees of pair-wise 
linkage disequilibrium (1000 Genomes Nov 2010 CEU) between the top SNP and all other genotyped SNPs. 
Genetic coordinates are per 1000 Genomes Nov 2010-CEU. Bottom, LD heat map based on D’ values from 
the combined population under study including all SNPs in the 500Kb region.
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other two GWS signals in 6q25.3 (SCLA22A3 locus) and 18q22.3, which have not been 
previously reported as associated with BD.
Meta-analyses
By scanning published BD GWAS, we identified a variant suggestive of association 
(P=6.01x10-7) [14], showing strong evidence for association with BD in our study, 
although not at GWS level. After meta-analysis of our results with those published by 
Kirino et al. in two Turkish cohorts the leading SNP (rs17810546) in IL12A reached GWS. 
The G-allele conferred a 1.7 increased risk for BD (OR= 1.66; 95%CI [1.42,1.93]; P= 1.12E-
10 (Table 3.)).
rs17087141
figure 5. snP association plot for Behçet’s susceptibility-associated region of Chromosome 18q22.3. 
Dots represent GWAS P-values (EMMAX approach) and positions of SNPs found within the 18q22.3 locus. 
The top SNP, i.e. rs17087141, is denoted by a diamond. Different colours indicate varying degrees of pair-
wise linkage disequilibrium (1000Genomes CEU) between the top SNP and all other genotyped SNPs. Ge-
netic coordinates are per 1000 Genomes Nov 2010-CEU. . Bottom, LD heat map based on D’ values from the 
combined population under study including all SNPs in the 500Kb region.
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replication
No significant evidence for replication of the leading SNPs from the GWAS signals of 
chromosome 6 and 18 was found, while the MAF of the genotyped markers were very 
similar to those reported in healthy individuals.
DIsCussIOn
Enabled by innovative novel methodology we could run a GWAS in a rare condition like 
BD within a unique case collection of multiethnic background. We identified variants as-
sociated with BD mapping to the well-established MICA-HLA-B locus and to two regions 
on chromosome 6 in the SLC22A gene region and on chromosome 18 in an unchar-
acterized region. Moreover, meta-analysis with previous published results enabled the 
identification of a GWS association with variants in the IL12A region. All together, these 
common variants across this four loci explained up to 32% of the variance in BD risk.
Methods for the calculation of heritability estimates from SNP microarray data of 
population-base studies have recently emerged [22, 23]. We could determine that the 
narrow sense heritability of BD explained by common variants in our study was 32%, 
estimate in line with those obtained by previous reports based on family data [3, 4, 28], 
albeit smaller. This could be explained by the overestimation of heritability estimates 
in family-based design, as a result of biases due to epistatic interactions or shared en-
vironment. In addition, GCTA estimates should be interpreted as the lower bound of 
the true additive genomic influence on heritability, since the genetic variance is limited 
to the common SNPs present in the arrays(29). Therefore variance explained by rarer 
variants (MAF<0.01) and/or causal variants that were not genotyped or are not tagged 
by the SNPs on the genotyping array will be missed. As GCTA is intended for studies on 
homogeneous populations it is necessary to use appropriate methods to calculate the 
relatedness matrix in studies with admixed individuals to avoid overestimation of the 
heritability. Therefore, to obtain unbiased estimates we used REAP for the estimation of 
the kinship coefficient [30].
Table 3. Meta-analysis of leading snP in Il12A. Association results for rs17810456 (G-allele) in two Turk-
ish cohorts (14) and the current study.
study n n cases Or CI 95% P value
Turkish replication* 2487 1209 1.64 [1.31 - 2.04] 1.20E-05
Turkish discovery* 1447 821 1.41 [1.06 - 1.89] 2.00E-02
Current study 6179 336 2.06 [1.49 - 2.84] 9.31E-06
Combined 10113 2366 1.66 [1.42 - 1.93] 1.12E-10
* From Table 1 Kirino et al. 2013
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Methods based on LMM enabled the analysis of GWAS data in a cohort of mixed eth-
nicity of relative small sample size, maximizing power. The fact that our GWAS identified 
well-established variants in the HLA-B locus, provides certainty that the methodological 
approach was sound and in fact applicable to other rare diseases. Expanding the current 
case collection or performing meta-analysis with other collections is warranted. Efforts 
including datasets of different ancestries, should be analyzed with methodologies which 
take into account different genomic architecture based on ethnic background. Such 
methods can also be applied at the meta-analysis level as implemented in MANTRA [31].
In addition to the signal in the well-known HLA locus on chromosome 6, we also 
identified two genomic regions of interest. Nevertheless, all variants had relatively low 
MAF (2-3%) and thus their significance should be interpreted with caution. We could not 
find evidence for replication of the associations in an independent yet underpowered 
case/control set. Considering the low MAF and the very limited power of the replication 
further scrutiny in an expanded dataset is required to confirm these variants as real or 
spurious associations.
Yet another GWS association with rs17810546 in the IL12A locus was identified by me-
ta-analyses of our results with those reported previously in the literature. These results 
support the role of this locus in the susceptibility of BD. Kirino et al., described this locus 
as suggestive for association with BD. In that study the variants did not were reach GWS 
in the combined analysis likely due to the variant being monomorphic in the samples 
of Japanese origin included in the study. Variants in CCR1-CCR3, STAT4 and KLRC4 which 
were polymorphic in both Turkish and Japanese populations surpassed GWS thresholds, 
suggesting that the lower power likely contributed to the non-significant findings in the 
IL12A locus.
BD is a rare disease, even in countries with the highest prevalence. Collecting the 
patient material for large multi-ethnic genetic studies proved to be challenging. Not 
surprisingly, the first two GWAS studies reported in BD were in two separate cohorts 
with a single ethnicity, a Turkish and a Japanese cohort [10, 11]. After meta-analyses of 
the data of both studies, polymorphisms in IL10 and IL23R–IL12RB2 proved to be associ-
ated at GWS level. In our study, these two polymorphisms were not associated with BD, 
nor in two other recent studies in Chinese and Korean individuals [32, 33]. Moreover, 
the GIMAP variants presented in the Chinese and a Korean cohort were not identified 
in the other studies. Recently, Ortiz-Fernandez et al., reported no association of GIMAP 
variants in a Spanish study but also acknowledged lack of power as a likely cause for 
this negative results [16]. Considering that most of our cases are of admixed ethnicity 
differences in ethnic background, specific pathology or clinical features of the cases are 
a more plausible explanation for the lack of replication of those variants in our study on 
top of limited power [32, 33].
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In conclusion we have shown that appropriate methodological approaches enable 
performing GWAS in cohorts of admixed ethnicity, combining cases of different ethnic 
origin as is often required in rare conditions like BD. As such, previously reported SNPs 
in the MICA-HLA-B locus reached GWS in the current approach. Additionally, we have 
shown that results of a mixed cohort can successfully be used in meta-analysis, by which 
we could establish the involvement of previously putative variant in the IL12A locus in 
the susceptibility of the disease.
Our results emphasize the need of collaborative efforts intending to enlarge the col-
lection of BD cases, which can enable a well-powered setting for detection of genetic 
associations with the disease, especially when interrogating low-frequency variants.
Potentially novel loci need to be further explored in additional studies, and ultimately 
coupled with functional studies, allowing a better understanding of the pathophysiol-
ogy and the genetic architecture underlying the risk for BD.
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supplementary figure 1. Behçet GwAs results using not adjustment for population stratification. 
Each dot represents an SNP in the dataset. a. QQ-plot. Associated SNPs deviating from the null hypothesis 
of no association (identity line) evidence high inflation. b. Manhattan plot. SNPs though all chromosomes 
show association with the disease.
rs2848713
rs7770216
rs4495304
supplementary figure 2 HlA regional Association Plot. GwAs results forBehcet susceptibility us-
ing linear Mixed Models approach. Top SNP rs2848713 EMMAX approach (MAF=0.10, A-risk allele) is de-
noted by a diamond. Marker rs7770216 is the top SNP for the Genomic Principal Components adjustment 
approach (MAF=0.25, T-risk allele). Marker rs4495304 is the top SNP in the association reported by Mizuki et 
al. (MAF=0.09, A-risk allele) for the GWAS of Behçet susceptibility without an. . Bottom, LD heat map based 
on D’ values from the combined population under study including all SNPs in the 500Kb region.
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InTrODuCTIOn
Behçet’s disease (BD) a systemic auto-inflammatory occlusive vasculitis, is character-
ized by oral and genital aphthous ulcers, skin lesions, ocular inflammation and the 
pathognomonic pathergy test(1-3). The etiology of the disease is largely unraveled. It 
is, considered to be an excessive inflammatory response triggered by an (infectious) 
antigen in a genetically susceptible host. Prevalences vary from 70–420 per 100 000 in 
the Middle East (Turkey) to about 1-7 per 100 000 in Western countries. In patients of 
Turkish origin there is positive family history in 12% of the cases with a sibling risk ratio 
between 11–52 [3, 4]. The heritability of BD has been estimated to range between 20 
to 60%. The strongest genetic association is with HLA-B51, it explains about 20% of the 
disease heritability [3, 4]. The combination of epidemiological and genetic data suggest 
causal involvement of both genetic and environmental factors(5).
Over the years numerous single nucleotide polymorphisms (SNP) have been found 
associated with BD(6-9). In 2010 the first genome-wide association study (GWAS) in BD 
cohorts of Turkish and Japanese origin demonstrated a range of variants in the HLA-B51 
domain, but also two new association signals, the interleukin-10 (IL10), and the IL-23 
receptor–IL-12 receptor Beta2 (IL23R–IL12RB2) locus(10, 11). These associations have 
been confirmed in an Iranian cohort(12). Another study in Algerian individuals only 
replicated the associations from the IL10 variants(13). GWAS in Chinese and Korean 
individuals reported associations of SNPs mapping to two other loci, with regions con-
taining the transduction and activator of transcription-4 (STAT4) and GTPase of immune 
associated protein GIMAP genes, respectively. Polymorphisms in IL10 and IL23R–IL12RB2 
were not found significantly associated in either of those studies(14,15). Most recently 
associations with CCR1, STAT4 and KLRC4 were identified by imputation analysis [14]. 
Kirino et al in this study identified the IL12a region as an area of interest but genome 
wide significance was not reached.
In GWAS a limited number of polymorphisms is examined, from 200.000 up to 600.000 
in BD studies. The number can be increased by imputation studies. However the largest 
part of the genome is neglected. Whole genome sequencing now enables to look at the 
complete genomic code. Performing such study in a family with multiple individuals 
afflicted by the disease simplifies the data analyses in order to identify genetic variants 
so far unknown.
We therefore performed a whole genome sequence study in five family members with 
3 BD patients and 2 healthy individuals.
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MATerIAls AnD MeTHODs
study population
Five family members were included in our study (figure 1). The father and two sons were 
BD patients, one son and one daughter are healthy individuals.
All patients fulfilled the International Study Group (ISG) criteria of BD diagnoses(15). 
No exclusion criteria were applied. All subjects gave their written informed consent.
1978
1936 II.3
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figure 1. Family with three BD patients (black boxes) and 2 healthy individuals (white boxes)
whole genome sequencing
Sequencing-by-ligation method from Complete Genomics (software version 2.5.0.33,
format version 2.5) as described by Drmanac et al. (2010) was used. The human ge-
nome sequencing procedures include DNA library construction, DNA Nano-Ball (DNB) 
generation, DNB array self-assembling, cPAL-based sequencing, imaging, image data 
analyses including base calling, DNB mapping, and sequence assembly. Reads were 
mapped to the National Center for Biotechnology Information (NCBI) reference genome, 
build 37. Variants were annotated using NCBI build 37 and dbSNP build 137. Data were 
provided as lists of sequence variants (SNPs and short indels) relative to the reference 
genome. Analysis of the whole genome sequencing data was performed using Com-
plete Genomics analysis tools (cga tools version 1.8.0; http://www.completegenomics.
com/sequence-data/cgatools/) and TIBCO Spotfire version 6.0.0 (build version 6.0.0.40) 
(http://spotfire.tibco.com/).
Data analyses
Data were analyzed using a python (2.7) script for multiple genome analysis, cga tools 
version 1.8.0 and Spotfire
6.0.0.40 (Tibco). Sequenced exome fraction (where weightSumSequenceCoverage >= 
40x) were 0.985 (Imm4) and 0.986 (Imm5).
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resulTs
DNA isolation failed in three cases, therefore genome sequencing was performed on 
DNA of the affected father and of a non-affected son.
IBS (indentity by sequence) analysis showed that both samples share one allele over 
99% of the genome, confirming the father and son relation.
In total 5,817,040 variants were detected in one or both family members, including 
single nucleotide variants (4,4681,960 and small insertions (713,715), deletions (429,173) 
and substitutions (205,956) (up to about 50 bp).
Of these, 410,868 variants were not present at all in any of the control samples (597 
wellderly samples, healthy individuals of over 85 years).
Regarding the inheritance pattern, we searched for dominant variants in the father 
that were not present in the non-affected son and in the healthy controls. (Genotypes: 
Imm4:00|0; Imm5:01|11|1 and allowing 2 No-calls)
165,768 variants were found, of which 75,162 variants were found in genes. 821 of these 
variants were protein affecting variants (PAV) in 732 different genes. 346 protein affecting 
variants (in 322 genes) had a high (H) varScore. The top 40 list is presented in table 1.
Table 1. Top 40 list of protein affecting variants identified by whole genome sequencing.
Chromosome Gene variant Chromosome Gene variant
chr10 DMBT1 chr9 ALDH1B1
chr1 RPTN chr5 TTC37
chr18 DLGAP1-AS3 chr12 KCNH3
chr1 C8A chr15 DIS3L
chr3 PFKFB4 chr11 LOC338667
chr13 FREM2 chr12 C12orf42
chr6 RNF146 chr17 FN3KRP
chr21 DNMT3L chr5 CARD6
chr1 ITGA10 chr2 NABP1
chr22 ISX chr22 PRR14L
chr6 PGC chr22 CLTCL1
chr9 KIAA0020 chr3 AMIGO3
chr10 NSMCE4A chr19 ZNF160
chr12 GLI1 chr5 PCDHGA10
chr1 MTMR11 chr1 VWA5B1
chr12 WSCD2 chr17 KIF19
chr5 CARD6 chr15 FMN1
chr19 ILVBL chr1 SLAMF9
chr12 PLBD1 chr10 LCOR
chr2 HIBCH chr13 NEK5
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These 346 PAV could be subdivided in: 269 missense; 37 frameshift; 18 insert; 13 dele-
tion; 6 nonsense; 2 disrupt and 1 nonsense variants.
DIsCussIOn
Over the years genetic associations have been identified by a candidate gene approach 
as well as GWAS approach. numerous single nucleotide polymorphisms (SNP) have 
been found associated with BD(6-13)(14,15). In order to identify new genetic variants 
we performed a whole genome sequence study in a family of BD patients. An exone 
sequence study in a different family identified TNFRSF9, MGEA5 and TNFAIP3 genes is 
possible candidates(16).
Due to a low yield in DNA we only analyzed the data of the father (case) and son 
(healthy). This led to a total of 346 PAV, a number too high for further analyzations. It 
identified interesting candidate variants that could be involved in BD, however it is not 
possible to focus on such number of genes. Variants identified earlier are not found in in 
our dataset. Therefore new patient material is collected en sequence analyses will be re-
done using all five family members of this unique family with such high incidence of BD.
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Cytokines in Beçhet’s disease

Cytokine profiles in tissue
Based on
Do synovial biopsies help to support evidence for involvement of the innate immunity in 
the immunopathology of Behçet’s disease?
Jan A.M. van Laar, Jasper H. Kappen, Paul.L.A. van Daele, P. Martin van Hagen
Arthritis Res Ther. 2009; 11(2): 109.
Cytokines in the colon of a patient with Behçet’s disease.
Jasper H Kappen, Willem A Dik, Gemma M Dingjan, Paul LA van Daele, Herbert Hooijkaas, P 
Martin van Hagen, Jan AM van Laar
Arthritis Res Ther. 2009; 11(4): 412.
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The etiology of BD is obscure, but considered a complex systemic vasculitis, caused by 
Th1-cytokine skewed neutrophillic and lymphohistiocytic inflammation. The innate im-
mune response is held responsible for the inflammatory symptoms occurring in patients 
with BD. Activation of BD can be triggered by exogenous factors such as skin damage, 
introduction of bacterial components, viruses or stress resulting in inflammation[1-3].
The association of HLA-B51 with BD and hyperactive neutrophils adds to assumption 
that BD is an “innate disease”[4]. Other factors supporting this assumption include; 
prevalence of symptoms at places in close contact with the outside environment 
(skin, mucosa, gut), hypersensitive T-cells, TLR expression in affected cells, hyperactive 
neutrophillic and CD8+T-cell responses to heat shock proteins or bacterial cell wall 
fragments[1, 3]. A normal inflammatory innate response is rapid, non-specific and self-
limiting. It contains a carefully balanced reaction between activated inflammatory cells 
and an exogenous trigger. In inflammatory disorders such as BD this response is disbal-
anced and causes excessive tissue damage.
Cytokines involved in BD are in great part pro-inflammatory (IL-1β, IL-8, IL-10, TNF-α 
and IFN-γ) and also associated with innate immunological patterns. Peripheral T-cells 
in BD patients express a predominant Th1-type cytokine pattern[5]. The rarity of BD 
and the lack of adequate in vitro or animal study models challenge to investigate im-
munopathological innate inflammatory patterns on the cytokine level in vivo. Therefore 
a model of easily reachable inflammatory material in BD patients with active disease is 
sparse.
Canete et al. describe a model of studying the immunopathology of BD by analyzing 
inflammatory cells, tissue and cytokines of inflamed joints from BD patients [6].
How does the study of Canete et al. add to biomechanistic studies already done in BD? 
First, in contrast to most of these studies analysis are performed in untreated patients. 
In an uncommon disease as BD, few studies in naïve patients are published. In RA for 
example, early and aggressive treatment is considered mandatory for optimal therapeu-
tic outcome. It will therefore be of great therapeutic importance to appreciate possible 
initiating factors in BD too by testing therapy-naïve patients. This is especially important 
for irreversible ophthalmic disease. Second, it is of importance that representative tis-
sue is studied. In BD most mechanistic studies are published on blood samples, and 
predominantly circulating cytokines or in vitro testing of PBMC’s is done. Th1 cytokines 
are involved, hyperactive neutrophils and hyper reactive T-cells are held responsible for 
the symptoms observed[7].
But BD is an inflammatory disorder with involving tissues such as skin, joints, eyes, gut, 
brain, oral and genital mucosa[1, 3]. It is therefore mandatory to known that observa-
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tions in the blood are comparable with bio-mechanisms on the tissue level. Mucosal 
tissue is predominantly involved in BD and microorganisms from the outside can easily 
influence observations on inflammatory cells. On the other hand, those microorganisms 
are also capable of stimulating an immune response in BD. Most tissue studies on the 
pathophysiology of BD are performed on the skin. One of the unique and disease specific 
features of BD is the occurrence of a positive skin pathergy reaction (SPR) varying from 
30–75% of all BD patients[1, 3]. Neutrophils and later lymphohistiocytic cells occur in 
sterile lesions induced by a sterile needle prick[8]. Representing endothelial injury and 
functioning as leukocyte trafficking factors, cell adhesion molecules (ICAM-1, VCAM-1) 
and endothelial growth factor markers such as E-selectin, P-selectin and endoglin are 
linked with SPR[9]. Infiltrating cells are mainly of the HLADR+/ CD3+/CD4+/CD45RO+ 
type[10]. Other observations include mature dendritic cells, monocytes, (regulatory) 
T-cells, elevated IFN-γ, IL-12-p40 and IL-15, MIP3-α, IP-10, Mig, and iTac, and adhesion 
molecules[11]. Studies of ocular BD show elevated Vgamma9Vdelta2 (CD4-/CD8-) and 
CD8brightCD56+ T-cells that are probably different than those found infiltrating the 
SPR[12] . Cytokines found elevated in ocular fluid of BD patients with active uveitis are 
IFN-gamma, TNF-α, IL-15[13]. It must be stressed however that aqueous humour is sel-
domly studied, difficult approachable and is only studied in intensively and long treated 
BD patients [14].
In contrast to most of the inflamed organs in BD, the joint is a sterile and often involved 
in BD patients [1, 3]. Canete et al. use this easily accessible model that has not been 
studied too often in BD. Previous, more than 30 year old, studies on BD arthropathy 
predominantly show neutrophillic infiltration depending on the stage and treatment 
of the disease. A more recent study in synovial fluid (SF) of BD patients show increased 
chemokines (CXCL-9 and CXCL-10) related with Th1-directed inflammation[15]). The 
group of Canete has studied SF extensively in various other arthropathies such as SpA, 
RA and comparisons might be made with historical data. SF of RA, juvenile SpA, juvenile 
polyarthritis, and juvenile oligoarthritis compared with SpA showed merely similar CD3, 
4 and 8 positive cells in all groups[16]. In the study presented it is concluded that PsA 
clinically resembles BD and probably also because in SF of PsA patients neutrophils are 
present. By showing increased intraartriculary CD15+ neutrophils, CD3+ T-cells, and 
perforin in SF of active BD patients as compared to PsA it can be emphasized that also 
in early BD the innate immunity is involved and interacts with the adaptive immunity 
reflected by perforin presumably secreted by CD3+Tcells. It might therefore be of inter-
est to further study on these naïve T-cells and cytokines in sterile SF in order to relate 
these observations with immunological patterns already described in a-sterile tissues 
that are exposed to exogenous factors, or more intensively treated BD patients. These 
results can then be compared with various other inflammatory diseases in order to ob-
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tain more insight in the immuno-etiology of BD and to develop more specific, molecular 
based immuno-therapy. Examples may include targeting cytokines (IL-1, IL-10, or IL6) 
and lymphocyte action interfering agents.
Cañete et al described cytokine patterns of inflamed joints from BD patients (BD)[6], we 
add to this an observation showing a similar cytokine profile in the colon of a BD patient 
with active disease, despite TNF-blocking treatment.
A 37-year old BD patient with severe colitis failed to traditional immunosuppressive 
treatment. Steroids were contraindicated because of a previous retinal serosal ablation, 
probably induced by prednisone. TNF-blockage initially successfully reduced the sever-
ity of the colitis, but relapses occurred. Variation of different TNF-blockers (etanercept, 
infliximab and adalimumab) could not permanently resolve the intestinal complaints. 
Antibodies against infliximab or adalimumab were not detected. Eventually, high dose 
infliximab (10mg/kg) and intravenous immunoglobulins (IVIG’s) led to disease regression 
facilitating a hemi-colectomy. Hereafter the patient’s condition improved significantly 
and IVIG’s were terminated whilst continuing TNF-blockage.
Cytokines were evaluated in the resected colon by analyzing mRNA expression levels 
of cytokine genes as previously described[17]. Because of the extensive prior treatment 
apparently healthy colon tissue of the patient served as internal control. Intestinal 
inflammation was patchy and the observed difference between healthy and diseased 
tissue was confirmed microscopically. The mRNA expression of cytokines in diseased 
colon is presented relative to those of healthy colon and can be seen as a reflection 
of intramural cytokines (Figure 1). Comparable to Cañete et al, we observed a Th1 and 
Th17-skewed pattern (elevated IFN-γ and TNF-α, and IL-17A, respectively). We could not 
demonstrate elevation of IL-10, possibly because our patient was intensively treated, 
and colon environment is not sterile.
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figure 1. mRNA expression of cytokine genes in diseased relative healthy tissue.
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Hence, understanding how cells and cytokines are functioning in inflamed tissues 
can be of great importance for therapeutic interventions[1]. In this light, one of the 
century’s most eye-seeing examples is that by blocking TNF-α, a key cytokine in BD, 
disease symptoms can be effectively and rapidly blocked too[2]. Most new treatment 
modalities will focus on blocking cytokines in specific pathways that play a key role in 
immunopathophysiology of BD.
BD’s immunopathology remains fascinating and highly relevant for the development 
of future, immune directed, therapy. Since the successful introduction of TNF-blockers 
it became apparent that Th1-cytokines might be key players in the immunopathology 
of BD, emphasizing the importance of cytokine studies[2, 3]. Our data add to Cañete et 
al that also in colonic tissue of a BD patient, IFN-gamma, TNF-alpha and IL-17A appear 
key cytokines, even in a treated patient. Maybe tissue cytokines reflect disease activity 
better than serum cytokine profiles.
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ABsTrACT
A 59-year old man with Behçet’s disease (BD) was referred with complaints of continu-
ous non-bloody diarrhea and abdominal pain since April 2006. On colonoscopy multiple 
aphthous lesions encompassed the entire colon showing a chronic merely neutrophillic 
infiltrate and oedema. Treatment with 30 mg prednisone and 200 mg azathioprine (AZA) 
was started. Attempts to lower the dose of prednisone led instantaneously to a relapse. 
In February 2007 symptoms worsened and mycophenolate sodium (MPS) was added, 
whilst tapering prednisone and AZA, yielding an immediate and sustained effect. Evalu-
ation with a double balloon scopy four months later showed that the colonic lesions had 
healed. In the terminal ileum that had not been reached in the first colonoscopy, some 
minor ulcerative lesions could be detected. Eleven months after initiation with MPS 
the patient remains in good clinical condition and improved symptoms with a reduced 
steroid and AZA dose.
Conclusions: This case shows that MPS might be a good therapy before using biologicals 
or chemotherapeutics in therapy-refractory BD patients with severe ileo-colitis. The 
involvement of the entire gastrointestinal tract in BD and the response to the therapy 
can be visualized using the double balloon endoscopy.
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InTrODuCTIOn
Although abdominal complaints may be regularly mentioned, gastrointestinal inflam-
mation occurs infrequently (1-5 %)in the Western population of patients with Behçet’s 
disease (BD), an idiopathic systemic vasculitis with oral and genital aphthous ulcers, skin 
lesions and ocular inflammation(1, 2, 3).
If present, aphthous lesions, erosions or ulcera, are most often reported in the termi-
nal ileum and right sided colon, leading to anorexia, vomiting, diarrhoea and abdominal 
pain [3, 4, 5]. Mucosal lesions in other parts of the small bowel and colon are rarely 
reported.
Although the etiology of BD remains unknown, it is generally considered an excessive, 
T-cell mediated inflammatory response, possibly triggered by an (infectious) antigen in a 
genetically susceptible host. The inflammatory cells in the lesions are of lymphocytic and 
monocytic origin. Neutrophilic infiltration is present in early lesions and might indicate 
innate immunity involvement in the pathophysiology of BD6. This suggestion might be 
supported by recent findings of SNP’s associated with a defective innate immunity in 
Crohn’s disease (CD), a disease clinically similar to BD [2, 7].
Most patients with BD only need symptomatic treatment. However, patients with 
gastrointestinal involvement are may require more aggressive treatment5. This includes, 
often combined systemic anti-inflammatory or immunosuppressive drugs such as cor-
ticosteroids, azathioprine (AZA), cyclosporine and sporadically other immunosuppres-
sives [2, 5]. The introduction of biological agents such as anti-TNF-α and interferon α 
has improved the therapeutic potential, also in intestinal Behcet [1, 2, 3, 8, 9]. In patients 
with therapy-refractory intestinal BD surgery might be the final therapeutic option [4].
Investigational drugs in BD are the mycophenolates, which are widely used in 
transplantation medicine and increasingly in autoimmune diseases such as CD, SLE 
and autoimmune rheumatic disease (ARD) [10, 11, 12]. Mycophenolate sodium (MPS) 
and mycophenolate mofetil (MMF) are prodrugs of mycophenolic acid (MPA), a strong 
inhibitor of the key enzyme monophosphate dehydrogenase (IMPDH). It suppresses 
both B- and T-cell proliferation, but also affects endothelial cells, including inhibition of 
TNF-alpha and neutrophil attachment [13].
We present the case of a patient with steroid and AZA refractory BD involving both 
colon and small bowel, treated with MPS and evaluated by double balloon endoscopy.
CAse
A 59-year old Caucasian man was referred from another hospital in December 2006. 
He complained of continuous non-bloody diarrhoea and abdominal pain since April. 
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On colonoscopy multiple aphthous lesions encompassed the entire colon (Figure 1a). 
Biopsies showed a chronic predominantly neutrophillic infiltrate and oedema. Other 
symptoms were papulopustular skin lesions, orogenital ulcers and arthralgia. BD was di-
agnosed. Treatment with mesalazine and later 30mg prednisone combined with 200mg 
azathioprine (AZA) only briefly relieved the complaints of diarrhoea, abdominal pain 
and arthralgia. Patient was referred to our hospital. Attempts to taper the prednisone 
below 30 mg instantaneously led to a relapse. In February 2007 symptoms worsened 
and 1440 mg MPS per day was added.
The effect was immediate, both AZA and prednisone could be tapered to 25 and 
2.5mg, within 2 weeks and 4 months, respectively (Figure 2).
Although some minor abdominal complaints were noted, orogenital ulcers, skin le-
sions and arthralgia disappeared. Four months later both colon and the entire small 
figure 1. A: Significant colitis with aphthous lesions in the distal colon in an untreated 59 year old patient 
with BD. B: Distal colon of the same patient 4 months after treatment with mycophenolate sodium and low 
doses of azathioprine and prednisone.
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Graph 1: Prednisone dose (triangles) in relation to the Behçet’s disease current activity (BDCAF, squares) 
score in a patient with BD and gastrointestinal involvement treated with mycophenolate sodium and aza-
thioprine (tapered swiftly from 200 mg to 50mg).
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bowel were evaluated by double balloon scopy. The colonic lesions observed previously 
in the entire colon had totally disappeared (Figure 1b). Some minor ulcerative lesions 
were detected in the terminal illeum which had not been reached at the first colonos-
copy. Biopsy showed a small amount of eosinophillic and neutrophillic infiltrates in the 
lamina propria surrounded by normal intestinal tissue (Figure 3). Eleven months after 
the therapy-switch the patient remains in good clinical condition (Figure 2).
DIsCussIOn
This case of effective additive treatment with MPS might support a basis for the use of 
a new class of therapy in BD patients. The double balloon endoscopy proves a valuable 
tool for evaluation of the entire intestinal tract.
A variety of immunosuppressive therapy is used in BD. In our patient TNF-blocking 
agents were considered, but preserved for a more severe or life threatening situation [8, 
9, 10]. Mycophenolates are increasingly used in the treatment of autoimmune diseases 
including uveitis and CD [12, 14]. Experience in BD is limited and to our knowledge 
there are no reports of its use in patients with gastroinestinal involvement. Adler et al. 
describes thirty patients with mucocutaneous BD quickly relapsing after initial response 
to MMF [15]. These relapses might be explained by the cessation of prednisone quickly 
after start of the MMF treatment. In our case tapering the other immunosuppressive 
therapy was monitored by the clinical condition and laboratory parameters. We there-
fore felt confident with the initiation of MPS in our BD patient. Up till now response lasts 
almost one year.
BD patients can have gastrointestinal complaints. Endoscopic evaluation was until 
recently restricted to the proximal and distal part of the small bowel and colon. Recent 
introduction of new endoscopic methods such as double balloon -or capsule endoscopy 
figure 3: Limited eosinophillic and neutrophillic infiltrates in the lamina propria of the terminal ileum after 
successful treatment with MPS in a patient with BD and gastrointestinal involvement.
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enables to visualize the entire gastrointestinal tract. Our case shows that the small 
intestine can be involved even in a BD patient with minor abdominal complaints. The 
additional value of these techniques might be helpful in diagnosing mucosal lesions 
in the small bowel of BD patients with abdominal symptoms and even may change the 
frequency of intestinal involvement. We therefore recently have initiated a prospective 
case study to observe intestinal involvement in BD patients with abdominal complaints.
In conclusion, this case shows that MPS might be used up front biologicals or chemo-
therapeutics in BD patients with ileo-colitis, refractory to corticosteroid- or AZA-therapy 
Tapering of instituted immunosuppressive medication may prevent an early relapse. The 
involvement of the entire gastrointestinal tract in BD and the response to the therapy 
can be visualised by double balloon endoscopy.
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InTrODuCTIOn
Behçet’s disease (BD) is an auto-inflammatory disorder, characterized by recurrent oral 
aphtosis, genital ulcers, uveitis and pustular skin lesions.[1] Associated cutaneous dis-
eases include Sweet’s syndrome,[2] erythema nodosum and pyoderma gangrenosum.
[3] Next to BD, both psoriasis and hidradenitis suppurativa (HS) are clear neutrophilic 
and IL-17-based diseases, suggesting a pathomechanistic overlap.[4-8] However, these 
diseases rarely co-occur.[4] Ustekinumab (anti-p40 mAb), an effective biologic treat-
ment for psoriasis, might be effective in BD by interfering with the IL-17 signalling via 
IL-23 blockage. We present a 39-year-old Caucasian woman, in which the combination 
of BD, psoriasis and HS, was successfully treated with ustekinumab.
CAse
At the age of 5, patient developed guttate psoriasis followed by psoriasis vulgaris with 
severe acne vulgaris since puberty. She started smoking at the age of 13 and periodically 
developed inflamed and tender boils in both axilla and groins during puberty. At 35, she 
was diagnosed with BD according to the guidelines of the international study group on 
BD based on oro-genital ulcers and uveitis anterior [4]. Inquiry learned that she repeat-
edly developed ulcers at injection sites, highly suggestive of a pathergy reaction. This 
was complicated by bilateral arthritis of the distal interphalangeal joints and weight 
loss due to multiple intestinal ulcers at the terminal ileum. Dermatological examination 
revealed vulvar and multiple circumscribed punched-out vaginal scars and ulcers, and 
fibrotic and rope-like scarring in the groins, together with HS, Hurley stage 2. The BD-
related symptoms prompted immunosuppressive treatment with diclofenac/misopro-
stol, ocular steroids, colchicine, intra-articular triamcinolone injection and cyclosporin, 
unfortunately all without with only temporarily effect. In the course of the disease she 
experienced an exacerbation of her psoriasis that was treated with subcutaneous injec-
tions of 45 mg ustekinumab at weeks 0, 4 and every 12 weeks thereafter. Fifty percent 
clinical improvement, as measured by the Psoriasis Activity and Severity Index (PASI 50), 
was achieved within 4 weeks, followed by PASI 75 within 3 months. Subsequently, both 
BD and HS skin complaints gradually decreased, and remained in complete remission for 
at least 36 months without adjunctive immunosuppressive treatment.
Before and 4 weeks after first injection of ustekinumab, serum was analysed using a 
semi-quantitative multiplex protein array to monitor changes in circulating cytokines, 
chemokines, and growth factors [5]. Before treatment, 64 out of 507 proteins, showed an 
increased, ≥ 2-fold expression compared to healthy control serum, including IL-23 and 
IL-12p70 (Table 1). Four weeks following the first injection of ustekinumab, 18 proteins 
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showed a change of more than 1.5 fold (Table 1), among which the Th1 and Th17-
associated proteins IL-12p70 and IL-23 were downregulated. These findings support an 
important role of Th1/Th17 pathways in BD [6].
There are only two other cases describing combined occurrence of BD and HS [7]. This 
case is the first in which these three diseases were simultaneously present. In addition, 
our case is the first BD patient reported that was effectively treated with ustekinumab. 
The successful treatment with ustekinumab provides a valuable addition to the current 
therapeutic armamentarium.
Table 1. Serum proteins compared to healthy controls and change induced by ustekinumab
Protein Fold change to
healthy controls (n=2)
Fold change by
ustekinumab
General function
IL-23 21,60 -2,18 Th17
Ciliary neurotrophic factor (CNTF) 12,08 -1,82 Il-6 family member
Osteoprotegerin 12,05 -1,68 Serum biomarker of artritis
IL-12 p70 7,71 -1,93 Th1
CCL27 7,37 -1,63 Th1/Th17
Glut2 5,56 -2,34 Glucose metabolism
VEGF 4,03 3,33 Angiogenesis
Kininostatin 3,70 -1,61 Angiogenic inhibitor
CCL3 (MIP1α) 3,45 -1,50 Th1/Th17
TRAIL R4 (TNFRSF10D) 2,82 1,62 Marker of inflammatory DCs
IGFBP-3 2,65 1,85 Growth factor
BMP-8 2,57 1,98 Growth factor
TGF-beta 2 2,29 2,06 Growth factor
FGF Basic 2,29 1,53 Growth factor
IGFBP-6 2,24 3,27 Growth factor
Inhibin B 2,14 2,51 Endocrine function
Neurturin 2,13 2,06 Neurotrophic factor
IL-24 2,04 2,85 Th17
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GenerAl DIsCussIOn
Behçet’s disease (BD) is a fascinating disorder. The epidemiology and pathophysiology 
of BD are widely debated, however, still need to be unravelled. This thesis encompasses 
translational studies to improve the insight in the demographic characteristics, geneti-
cal background, immunopathophysiology and treatment modalities of BD. Each chapter 
elaborates on specific segments of these subjects. In Chapter 2 it is argued that the 
prevalence of BD, contrary to a general assumption, doesn’t decrease after migration. 
Also we correlate specific disease features to ethnical background. In Chapter 3 we 
demonstrate that some genetic variations are protective and others are associated with 
a higher risk on BD. We also demonstrate that it is possible to run a GWAS in a rare condi-
tion like BD in a cohort of multi-ethnic background. In Chapter 4 we show that cytokine 
profiles in affected tissue seem to be more relevant than serum cytokine profiles. Finally 
in Chapter 5 we present new treatment modalities such as TNF-α blockers, that success-
fully can be applied in BD patients. In this final Chapter we will discuss the results and 
implications of all initiated studies as well as the and suggestions for further research.
Pathophysiology
In Chapter 1 an overview on the pathophysiology of BD is presented, indicating that BD 
is a multifactorial auto-inflammatory vasculitis occurring in virtually all types of blood 
vessels, with a certain genetic predisposition, in combination with various environmen-
tal factors, leading to inflammation [1-4] (Figure 1).
The inflammation is characterized by a Th-1 and probably also Th-17 mediated im-
mune response(4, 5). In the early phase of inflammation granulocytes and gamma-delta 
T-cells (Tγδ) are identified in the affected tissues(6). These are believed to be activated 
by environmental "triggers" [7]. Several cytokines are involved in the event mechanisms. 
Starting with IL6, produced by antigen presenting cells, which promotes the differentia-
tion towards Th1 cells and IL23, produced by Tγδ cells that promotes the Th17 differ-
entiation P40 [8, 9]. The central cytokine in the inflammatory process is tumor necrosis 
factor (TNF) -α, which is produced by virtually all the cells involved. TNF-α subsequently 
activates the production of other cytokines including IL-6, IL-8, IL-10 and IL-17.
epidemiology
BD is a disease that is traditionally associated with countries along the former Silk Road, 
an ancient route of commerce from the Mediterranean Sea to the Far East (China). In 
Turkey occurs the highest prevalence: 20-420 cases per 100,000. In Asian countries, such 
as Japan, Korea, China, Iran and Saudi Arabia, prevalences vary from 13.5 to 20 cases per 
100,000. In Western- European countries prevalences ranging from 1-7.5 per 100,000 are 
reported (figure 2) [10-12].
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figure 1; Immunopathophysiology of Behçet’s disease
It is assumed that stimulation by pathogens of granulocytes, Tγδ and DCs, in a genetically predisposed host 
a cascade of inflammatory cytokines eventually lead to vascular damage and vasculitis.
Abbreviations: IL; interleukin, TNF; tumor necrosis factor, Tγδ; Tγδ subset T cells, Th; CD4 + cells Thelper, DC; 
dendritic cells
 
 
 
figure 2: Prevalences of BD in different countries. Printed with permission from prof. dr. A. Mahr [12]
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A remarkable phenomenon often referred to, is a decreasing prevalence of BD after 
migration. Zouboulis et al. presented that the prevalence of BD in a Turkish population 
decreased after migrating to Germany [13]. The data, however, could not be repro-
duced by the same group in another study in that was published later in 2012 [14]. A 
similar observation was presented in 1976 amongst Japanese immigrants on Hawaii. 
The prevalence of BD in Japan is 7-13.5 per 100,000 whereas the prevalence amongst 
the Japanese population on Hawaii is reported 0 [15]. However in 1976, about 800,000 
inhabitants lived on Hawaii with 13% Japanese immigrants. It can be assumed that at 
least 13 BD patients of Japanese origin must be living on Hawaii. Such low numbers 
however, can easily be missed in epidemiological studies. We addressed these issues by 
identifying all BD patients treated in the Rotterdam postal area. In Chapter 2 we show 
that the prevalence of BD in the Rotterdam area in three ethnic groups, Dutch, Turkish 
and Moroccan, is 1, 72 and 35 per 100,000 respectively. This is completely in line with 
comparable epidemiological studies in other cohorts with similar ethic background and 
also with the prevalences of BD in the aforenamed countries. For example, BD amongst 
the Turkish population in Germany is found to be 72 per 100.000, which is similar to 
the reported prevalence in the European part of Turkey(14). Additionally, the fact that 
substantial numbers of our Turkish (up to 20%) and Moroccan patients is born in the 
Netherlands underlines that environmental circumstances are not decisively dictate the 
ability to develop BD and does not appear to be involved in the pathogenesis of BD.
The average age in our BD cohort is about forty years and does not differ amongst vari-
ous ethnicities, while male/ female ratio is lower in Dutch-Caucasians as compared to 
Moroccans and Turks (Chapter 2) [16, 17]. These variations in male/ female ratios in dif-
ferent ethnic groups are comparable with observations in other cohorts [18, 19]. Saylan 
et al reported female predominance in the United States, the United Kingdom, Korea 
and China, whereas a male predominance was found for almost all Middle Eastern coun-
tries [20]. The cause of the female preference in Western and Asian countries remains 
unknown. But it is known that low male/ female ratio is often seen in auto-immune 
diseases. BD, however, is considered be an auto-inflammatory disease which is not as-
sociated with female predominance(21, 22). Secondly, underdiagnosing of BD in women 
in Middle Eastern countries can arguably be explained by the suggestion that women 
might visit less frequent their physician than men in these regions. Possibly female 
preference is present all regions, new reliable data is needed to clear this debate.
Relevant differences between ethnic groups in disease features is limited. Surprisingly we 
encountered a significantly higher percentage skin involvement in our cohort as com-
pared with Germany and Morocco (Chapter 2). We expected to see more skin involvement 
in countries with high disease prevalence since environmental factors are considered of 
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great importance. Our data indicates that other factors, such as genetic susceptibility 
might be of more relevance than environmental factors which is supported by the ob-
servations of stable prevalences after migration as described in the first part of Chapter 2.
We also observed a significantly higher prevalence of uveitis in our Western cohort 
(which consists of Caucasians, Turks and Moroccans) as compared to Turkish and Mo-
roccan cohorts (Chapter 2). Considering the rarity of BD in the Netherlands it can be 
argumented that BD is easily missed in patients presenting with oral ulcers. A relative 
underdiagnoses of the less severe cases of BD might lead to relatively higher prevalence 
of severe case with uveitis. Additional education on BD might minimalize this effect. This 
thesis can be used as a starting point for educational purposes in the future, possibly 
facilitated by the patients associations. An additive reason for the high percentage of 
uveitis found in the Erasmus MC cohort is the close cooperation between our hospital 
and the Rotterdam Eye Hospital hence referral of selected patients. Future research can 
focus on collecting a substantial amount of patient data to elucidate migrational effects 
on the occurrence and morbidity of BD more robustly.
Genetics
Over the years it has been widely accepted that there is a genetic component in the 
etiology of BD. In patients of Turkish origin there is positive family history in 12% of the 
cases with a sibling risk ratio between 11–52 [4, 14]. The discovery of the association 
with HLA-B51 has been the first breakthrough, explaining about 20% of the heritability 
of BD [4, 14]. Over the years numerous single nucleotide polymorphisms (SNP) have 
been found associated with BD(2, 23-25). The initial approach of candidate gene selec-
tion has been based on clinical similarities with other diseases. The candidate disease for 
this matter might be CD, both disorders share many symptoms (figure 3).
In this light, specific similar symptoms such as uveitis, arthritis, erythema nodosum and 
colitis with ileocecal mucosal inflammation and punched-out fissuring ulcers suggest 
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 figure 3: Symptoms of CD and BD
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a possible genetic overlap between BD and CD(3, 26). Since CD has been associated 
with variations in NOD2 innate immunity, the NOD2/ CARD15 gene, we hypothesized 
that BD, considereding its association with innate immune malfunctioning, might be 
associated with the same variants [27, 28].
Surprisingly and contrarily at first, we determined a protective association between 
BD and the NOD2 variants (Chapter 3). In a protective association the variants are 
significantly less present in the patients as compared to the control group. Previous 
reports showed no association nor a protective association. A low prevalence of NOD 
variants in Turkish individuals however, was presented previously [29, 30]. Possibly the 
cohort sizes of the other studies were too limited to detect the protective association. 
Our observation was confirmed in 2013 by Kirino et al. in a targeted resequence study in 
Turkish and Japanese individuals [31]. Their study confirmed our results and hypotheses 
by demonstrating NOD2 variants are associated with a higher risk in CD, but a lower 
risk on BD. The exact mechanisms of this finding are unclear and have not functionally 
been tested. In CD both gain of function and loss of function mechanisms are proposed 
to explain the involvement of NOD2 variants. A loss of function might possibly lead 
to decreased NF-кB activation and thus reduced defensin production resulting in an 
increased bacterial load in the gut of CD patients and subsequently an inflammatory 
response with tissue damage (figure 4b) [32-34]. On top of that, NOD2 activation inhibits 
stimulation of Toll-like receptors by pathogen products, and as NOD2 function is im-
paired, TLR signaling is enhanced and generates an exaggerated inflammatory response 
inducing tissue damage [32, 33].
Another hypothesis is based on the observations in a second model. Here transgenic 
expression of the Leu1007fs variant show a gain of function, with a direct increase in NF-
кB, pro-inflammatory cytokines and tissue damage (figure 4a and 4c) [32]. A potential 
connection between these paradoxical results lays in the kinetics of the NOD2 response. 
Normally, acute stimulation of human blood-derived macrophages with the NOD2 
agonist, muramyl dipeptide (MDP) induces a pro-inflammatory cytokine response. By 
comparison, persistent treatment of cells with MDP prior to activation through TLR2 or 
TLR4 ligands decreases cytokine responses (tolerance), possibly through induction of 
IRAK-M, in support of control of TLR signaling. However, this tolerance is lost in cells from 
patients homozygous for the mentioned Leu1007fs homozygous patients leading to 
higher cytokine levels and more inflammation [35]. As gut epithelial cells, dendritic cells 
and macrophages are in constant contact with bacterial products of the normal gut flora 
it is proposed that such tolerance is a protective mechanism, loosing this tolerance leads 
to a failure to control responses and eventually leads to tissue damage as seen in CD [36].
The observation in this thesis that NOD2 variants decrease the risk on developing BD 
suggest that under continues or repetitive exogenous stimulation, NOD2 variants in BD 
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patients lead in some cases with a decreased production of inflammatory cytokines. 
Thus patients without this mutation would not be able to control their inflamma-
tory response. This loss of function model is supported by the observation that NOD2 
gene-deficient mice show reduced joint inflammation and are protected against early 
cartilage damage after intra-articular injection of MDP through Streptococcus pyogenes 
cell wall fragments [37].
After some reluctance it is now widely accepted that NOD2 plays a role in the patho-
physiology of BD, since the complex role of NOD2 in response to bacterial challenges in 
different cell types more functional analyses.
As compared to the targeted candidate gene approach, Genome Wide Association 
Study (GWAS) involve the other spectrum of genetic evaluations in the search for disease 
modifying variants. In GWAS one assay compares multiple variations (up to 600.000) 
between patients and controls. Since GWAS results can be confounded by ancestry 
differences between cases and controls, potentially leading to spurious associations, 
novel statistical methodology such as Genomic Principal Components (GPC) and Linear 
Mixed Models (LMM) to correct for these for ancestry differences have been applied. 
These correct also for family structure and cryptic relationships [38]. In order to gain 
enough power in these statistical analyses, large cohorts are used to identify possible 
figure 4: Possible mechanisms of Crohn's disease in patients with mutations in CARD15 [32]. Printed with 
permission Strober W, Murray PJ, Kitani A, Watanabe T. Signaling pathways and molecular interactions of NOD1 
and NOD2. Nature reviews Immunology. 2006;6(1):9-20.
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associations. In 2010 the first genome-wide association study (GWAS) in BD cohorts of 
Turkish and Japanese origin demonstrated association of various variants in the known 
HLA-B51 domain, and two new association signals, mapping to the interleukin-10 (IL10), 
and the IL-23 receptor–IL-12 receptor Beta2 (IL23R–IL12RB2) locus [39, 40]. These associa-
tions have later been confirmed in an Iranian cohort [41]. Yet another study in Algerian 
individuals only replicated the associations from the IL10 variants [42]. GWAS in Chinese 
and Korean individuals reported associations of SNPs mapping to two other loci, with 
regions containing the signal transducer and activator of transcription 4 (STAT4) and 
GTPase of immune associated protein GIMAP genes, respectively. Polymorphisms in 
IL10 and IL23R–IL12RB2 are not found to be significantly associated with BD in neither 
of those studies [43, 44]. More recently, associations with CCR1, STAT4 and KLRC4 were 
identified by means of imputation and GWAS meta-analysis [45]. This study also identi-
fied the IL12A region as suggestively associated with BD, but genome wide significance 
(GWS) was not reached. Discrepant association results, as those observed for variants 
mapping to the GIMAP locus, might be explained by the different ethnic origin of the 
cohorts studied(46, 47). Therefore, studying cohorts of diverse ethnic background 
may be useful to understand the origin of these differences. Moreover, the inclusion 
of multiple ethnicities results in larger datasets (representing higher power) crucial for 
these analyses given the typically small effects of common genetic variants discovered 
by the GWAS approach [48]. Enabled by innovative novel methodology as GPC and 
LMM we could run a GWAS in a rare condition like BD within a unique case collection of 
multiethnic background (Chapter 3). We identified variants associated with BD mapping 
to the well-established MICA-HLA-B locus and to two regions on chromosome 6 in the 
SLC22A gene region and on chromosome 18 in an uncharacterized region. Nevertheless, 
all variants had relatively low MAF (2-3%) and thus their significance must be inter-
preted with caution. We could not find evidence for replication of the associations in 
an independent yet underpowered case/control set. Considering the low MAF and the 
very limited power of the replication further scrutiny in an expanded dataset is required 
to confirm these variants as real or spurious associations. Yet another GWS association 
with rs17810546 in the IL12A locus was identified by meta-analyses of our results with 
those reported previously in the literature, Kirino et al., previously labelled this locus 
as suggestive for association with BD. In that study the variants did not reach GWS in 
the combined analysis likely due to the variant being monomorphic in the samples of 
Japanese origin included in the study. Variants in CCR1-CCR3, STAT4 and KLRC4 which 
were polymorphic in both Turkish and Japanese populations surpassed GWS thresholds, 
suggesting that the lower power likely contributed to the non-significant findings in the 
IL12A locus. All together, the common variants across this four loci identified in our study 
explained up to 32% of the variance in BD risk.
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The role of IL12A in the pathophysiology of BD might be explained by its function. 
IL12 is a heterodimer composed of two chains, IL12A, also commonly known as the 
P35, and IL12B (or P40) [8, 9]. IL12A (P35) shares homology with other cytokines such 
as IL6, while IL12B (P40) is one of the chains of another heterodimer, IL23. An important 
function of IL12 is the promotion of the differentiation of naïve T-cells to Th1 subsets 
and subsequently the production of IFN-γ. BD is considered to be an Th1-cell mediated 
disease. IL12A variants in a gain of function manner can lead to an overexpression of 
Th1-cells. Differentiation to Th17 subsets is initiated by IL6 and IL23. IL6 shares homol-
ogy with IL12A (P35) while one of the dimers of IL23 is IL12B (P40). Possibly IL12A (P35) 
variants together with yet unidentified variants in IL12A (P35) and IL12B (P40) lead to 
observed elevated Th17 subsets in BD(49). Moreover, involvement of the IL12 and IL23 
pathway is also supported by the identification of variants in the IL23R–IL12RB2 region 
in the first GWAS presented in BD [39, 40].
Some variant that have been identified in the last years are involved sensing of 
pathogens and other variants are more involved in the regulation of the immune system 
(figure 5) [50]. Potential implications of this hypotheses are that in an early phase of 
the pathophysiological events a defect in pathogen sensing, mainly the innate immune 
system must be involved. As a result the immune response is out of balance and the 
regulation is lost. In this phase several organs can get involved in the disease, even when 
the initial stimulants is already gone. The pathogenomic pathergy skin prick test would 
be a reflection of the early phase.
Sensing and processing
CCR1
TLR4
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NOD2
HLA-B51
Exogene and
Endogenous
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figure 5: Genetic variants involved in the pathogeneses of BD, adapted from Gul A. Genetics of Behcet's disease: 
lessons learned from genomewide association studies. Current opinion in rheumatology. 2014;26(1):56-63. [50]
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The next step to unravel the pathogenetics of BD would be a whole genome sequence 
study in which a complete genome is scanned for variants related to the disease. By 
analyzing subjects and controls from one family covariants can be filtered out. Our 
sequence study unfortunately had a low yield in DNA isolation in 3 of the 5 subjects 
(Chapter 3). The result was a list of 340 genes that possibly are involved in BD. This 
number is too high for further processing. Future research should therefore focus on 
whole genome sequencing in families to identify genes that so far could not be linked 
to BD. Subsequently mechanistic studies are needed to understand the exact effects of 
the variants such as IL12A and NOD2 and the inflammatory implications in the cytokine 
cascade in the disease mechanisms. In the next chapter we address the value of measur-
ing these cytokines in BD patients.
Cytokines profiles in Behçet’s disease
Apart from the genetic studies in order to identify pathways and target cytokines in-
volved in the pathophysiology of BD we also looked for clues in cytokine levels in BD 
patients. In the past several cytokines have been linked to the pathophysiology of BD, 
such as IL12 and IFN-γ as traditional Th1 cytokines and more recently IL23 and IL17 [5, 
51-53]. Also elevated serum levels of the Th2 cytokine IL10, that normally inhibits the 
Th1 response, are found in BD patients [54]. Last, but not least, TNF-α that appears to 
play a central role in many auto-immune and auto-inflammatory disease and also in BD. 
TNF-α is produced by virtually all cells involved and subsequently activates the produc-
tion of other cytokines such as IL -1β, IL-6, IL-8, IL-10 and IL-17. Other inflammatory cells 
are attracted to the inflammation site and contribute to an inflammatory infiltrate.
Most studies in the pathophysiology of BD focussing on cytokine levels concentrate 
on serum profiles. In Chapter 4 we relate elevated IFN-γ, IL-6 and IL-10 levels with active 
small bowel (SB) involvement in BD. These cytokine profiles however, are not typically 
Th1 nor Th17 patterns as we would have expected based on the current opinion of the 
involvement of the Th1 and Th17 axes in the pathophysiology of BD. The increased IL-10 
levels could be either part of the pathogenesis of intestinal BD as well as a physiological 
response on inflammation in these patients. In addition to this, although in both SB-
positive and negative BD patients cytokine profiles were measured, immune modulat-
ing treatment of the B-positive group might have been more profound and therefore 
influenced these observations as well as the composition of the blood lymphocyte com-
partment in our study [55-57]. Since this study population has been limited in size with 
different types of immunosuppressive treatment between patients it remains difficult to 
draw any firm conclusions on the clinical use of cytokines and lymphocyte subsets, but 
IFN-γ levels might be of importance.
More interesting are the cytokine levels in affected tissue. Also in Chapter 4 we 
demonstrate high mRNA expressions of IFN-gamma, TNF-α and IL-17A in affected tissue 
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of intensively treated patients. As previously mentioned all are key cytokines in BD. In 
this perspective of the few data available, also in synovial fluids of naïve BD patients a 
similar Th1 skewed pattern has been demonstrated, it didn’t report on IL17A [58]. We 
know that serum cytokine profiles not always seem to correlate with disease activity and 
suspect that serum cytokine profiles not always reflect the inflammation on tissue level. 
We therefore conclude that more data in cytokine profiles on tissue levels in comparison 
with serum levels is needed. These measurements might have implications on the devel-
opment and possibly monitoring of targeted therapy in BD.
new treatment modalities
BD is a disease in which symptoms usually respond well to a wide variety of immuno-
suppressive therapy. Depending on the severity of the disease and involvement of vital 
organs immunosuppressives are titrated (table 1).
Table 1: Current immunosuppressant treatment used for Behçet’s disease
Medication Dose Main indications
Prednisone Local
Systemic: 0.5 – 1 mg/kg
Uveïtis
Mucocutaneous involvement
Induction treatment uveïtis
Neurological involvement
Refractory arthritis
Gastro-intestinal ulceration
High apoptotic dose iv: 1g/day, 
1-3 times iv
Life-threatening disease, or severe neurological 
involvement
Colchicine 0.5 - 1.5 mg / day Skin involvement
Arthritis
Dapsone 100 - 200 mg / day Mucocutaneous involvement
Arthritis
Azathioprine 2 - 3 mg / kg / day Uveitis
Pentoxifylline 1200 mg /day Mucocutaneous involvement
Sulfasalazine 1- 3 g / day Mucocutaneous involvement
arthritis
Thalidomide 50 - 200 mg / day Refractory mucocutaneous involvement
Cyclosporine 2 dd 3 - 5 mg/kg / day Uveïtis
Mucocutaneous involvement
Methotrexate 7.5 - 15 mg / week Arthritis
Uveitis (rarely)
Cyclophosphamide 750 mg / m2 /mo IV Life threatening involvement (vasculitis, neurological)
IFN-α-2a 9 million units /week for 3 months 
followed by a low maintenance 
dose of 3 million units /week)
Uveitis
TNF- blockers Various doses Uveitis
Arthritis
Gastro-intestinal ulceration
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In Chapter 5 we also present data of a patient that was successfully treated by Myfortic 
(mycophenolate sodium (MPS)), we feel that MPS can be added to this list, at least for 
patients with intestinal BD.
Every immunosuppressant has its own, unique, point of action in the pathophysiologi-
cal events in the inflammatory process in BD. New insights in this pathophysiology with 
the identification of novel cytokines and pathways by either genetic studies or cytokine 
studies can therefore be used for the development of new treatment modalities using 
biological agents (or biologicals). Most biologicals are exerting their effect by blocking, 
such as for example a key cytokine such as TNF-α [59, 60]. TNF-α blockers are increas-
ingly used and described in refractory BD, particularly in patients with uveitis or colitis 
[61-66]. Evidence for efficacy of the TNF-blockers infliximab and adalimumab in BD is 
emerging. We add to this data of for adalimumab in refractory BD patients presented in 
Chapter 5. Some retrospectively studies already have demonstrated the improvement of 
clinical symptoms in BD patients treated with adalimumab [66, 67]. Also case-series with 
adalimumab report major responses of BD-related symptoms [64, 65]. Although studies 
with BD patients treated with infliximab involve in total 174 patients in 16 publications, 
limited data with adalimumab is available [64]. Therefore we followed 9 patients with 
therapy refractory BD that were treated with abalimumab. We observed a 100% response 
rate, the disappearance of oral ulcers and erythema nodosum, and the possibility to 
taper or terminate other anti-inflammatory drugs. Our observations are in line with 
other long term follow-up retrospective BD studies with adalimumab and the long term 
effects of this TNF-α blocker in other inflammatory diseases [65, 66, 68, 69]. Furthermore, 
adalimumab appears safe immunosuppressive therapy consistent with other reports of 
TNF-blockers in BD [60, 64, 70]. The low number of relatively minor adverse effects and 
its clinical activity implicate that adalimumab is as potent as its intravenous alternative, 
infliximab. Consensus on the indications for the use of TNF-α blockers, for example using 
a phenotypic approach; e.g. intestinal BD, ocular BD, as well as data when to stop the 
therapy is still needed. Future research might focus on these aspects helping treating 
physicians in the choice and the duration of TNF-α blocking therapy.
By blocking TNF-α a multi-functional cytokine is blocked, while ustekinumab (anti-P40) 
blocks a more specific pathway, IL23 and IL12. In our GWAS we identified IL12A variants 
related to BD, furthermore we observed elevated levels of IL17 on tissue level in one of 
our BD patients. We therefore postulated that blocking P40 might lead to better disease 
control. We used anti-P40 in a patient with a combination of BD an HS. It proved to be an 
effective treatment in this case. We feel that cytokines and pathways involved in BD as well 
as the result in this case support the need for exploration of the effect of anti-P40 in BD.
Only anecdotal data is present on other biologicals such as anti-IL1 (anakinra) or anti-
IL6 (tociluzimab), however genetic data and cytokine data suggest a possible positive 
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effect by blocking the targets of these agents, namely either IL-1 or IL-6. . In the ideal 
world it would be most efficient if various mechanistic pathways could be blocked si-
multaneously, however this has so far not been exerted.
In conclusion
The pathophysiology of BD is complex, both genetic as environmental factors might 
play a role. In this thesis we have challenged the assumption that the prevalence of 
BD decreases after migration. Combined with specific apparent ethnical related disease 
symptoms this might accentuate the importance of the genetic compound in the 
pathogenesis in BD. We added proof to these increasing insights with the determination 
of variants of NOD2 and IL12A in patients with BD. Malfunctioning of these genes might 
be reflected by the cytokine patterns involved in the inflammatory cascade known in 
BD. The elevated levels of Th1 -as well as Th17 cytokines in in both tissue and serum of 
patients with active BD, described in Chapter 4 fit in this pattern and suggest that BD 
is more than a Th1 mediated disease. These findings can help us in the development of 
new treatment modalities and our understanding of the immunopathophysiology of 
BD. The key-cytokine in the inflammatory process of BD, TNF-α seems to play a central 
role (figure 6). Blocking TNF-α as described in Chapter 5 effectively down regulates the 
figure 6: Pathophysiology of BD, white boxes show variants or cytokines identified in this thesis related to 
BD. Blocking P-40 will block Th1 promotion as well as Th17 promotion. Blocking TNF-α will lead to a broader 
down regulation of the inflammatory response.
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inflammatory response. In case of therapy failure or intolerance to TNF-blockers new 
agents, such as ustekinumab (anti-P40) can secure or even enhance therapeutic efficacy 
via another inflammatory pathway by blocking the promotion of Th1 production by 
IL12 as well as blocking the promotion of IL17 production by IL23. Translational research 
is and will be the cornerstone in the development of new molecular designed drugs, 
single or combination therapies of monoclonal antibodies that might more effectively 
block different inflammatory pathways in order to overcome escaping mechanisms.
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suMMAry
Behçet's disease (BD) is an multifactorial auto-inflammatory vasculitis characterized by 
recurrent oral -and genital ulcers, uveitis, and skin lesions. The first series of patients 
with BD was already published in 1937 as a triad of these symptoms. Less frequently, 
involvement of the gastrointestinal tract, central nervous system and large vessels may 
occur. As in other immune mediated disorders BD is characterized by attacks rather than 
by a persistent inflammatory symptoms. Cases of BD cluster along the ancient Silk Road, 
which extends from eastern Asia to the Mediterranean basin. The reported prevalence 
in Turkey varies between 70 and 420 per 100.000. In Northern European countries how-
ever, the prevalence is probably less than 1 per 100.000 in Caucasians. It is believed that 
both genetic and environmental factors contribute to the development of the disease. 
Men might be more frequently and severely affected than women Susceptibility to BD 
is strongly associated with the presence of the HLA-B51 allele and its presence is also 
strongly associated with a more aggressive course. The cause of BD, however, is still 
unknown. Triggers such as infections, both viral and bacterial, trauma, and other stress 
factors may play a role in the inflammatory process.
Although the exact pathophysiology of BD remains to be elucidated, it is clear that 
neutrophils interacting with T-cells play an important role. Activated T-cells produce 
TNF-α, leading to production of other proinflammatory cytokines like IL1 and IL6. These 
proinflammatory cytokines stimulate migration and activation of leucocytes, thereby 
causing a local inflammatory response. In this thesis translational aspects of BD on areas 
of epidemiology, genetics, cytokines and new treatment modalities will be linked with 
these immuno-payhophysiological features.
In Chapter 2 it is argued that the prevalence of BD, contrary to the general assumption, 
doesn’t decrease after migration. Also we correlate specific disease features to ethnical 
background. Prevalences of BD in the Rotterdam area differed per ethnicity; 1, 71 and 
39 per 100.000 for Dutch-Caucasians, Turks, and Moroccans, respectively. These figures 
are similar to other cohorts in countries were BD prevails. The first epidemiologic study 
of BD in the Netherlands initiated by the Erasmus MC demonstrates, in 110 patients 
no significant differences in morbidity between ethnic groups. However, uveitis and 
pustules were significantly more present in the EMC cohort as compared to UK, German, 
Turkish and Moroccan cohorts.
The heritability of BD has been estimated to range between 20 to 60%, with the stron-
gest genetic association embracing variants in HLA-B51, explaining about 20% of the 
disease heritability. The combination of epidemiological and genetic data suggest causal 
involvement of both genetic and environmental factors. In Chapter 3 we demonstrate 
that some genetic variations are protective and others are associated with a higher risk 
on BD. We also demonstrate that it is possible to run a GWAS in a rare condition like BD in 
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a cohort of multi-ethnic background. In patients of Turkish origin there is positive family 
history in 12% of the cases with a sibling risk ratio between 11–52 .
Over the years numerous single nucleotide polymorphisms (SNPs) have been found 
associated with BD. We are the first to identify a protective association with NOD2 vari-
ants. In 2010 the first genome-wide association study (GWAS) in BD cohorts of Turkish 
and Japanese origin demonstrated association of various variants in the known HLA-B51 
domain, and two new association signals, mapping to the interleukin-10 (IL10), and the 
IL-23 receptor–IL-12 receptor Beta2 (IL23R–IL12RB2) locus. Other associations identified 
in GWAS are signal transducer and activator of transcription 4 (STAT4), GTPase of im-
mune associated protein GIMAP genes, CCR1, STAT4 and KLRC4.
We ran a GWAS on 336 BD cases and 5,843 controls. The cases consisted of Western 
Europeans, Middle Eastern and Turkish individuals. Participants from the Generation R 
study, a multiethnic birth cohort in Rotterdam, The Netherlands were used as controls. 
Linear regression models were corrected for population stratification using Genomic 
Principal Components and Linear Mixed Modelling. Meta-analysis was performed on 
selected results previously published. We identified SNPs associated at genome-wide 
significant (GWS) level mapping to the 6p21.33 (HLA) region. In addition to this known 
signal two potential novel associations on chromosomes 6 and 18 were identified, yet 
with low minor allele frequencies. Extended meta-analysis reveal a GWS association with 
the IL12A variant rs17810546 on chromosome 3.
In Chapter 4 we show that cytokine profiles in affected tissue seem to be more rel-
evant than serum cytokine profiles. The central cytokine in the inflammatory process in 
BD is tumor necrosis factor (TNF) -α, which is produced by virtually all the cells involved. 
TNF-α subsequently activates the production of other cytokines such as interleukin (IL) 
-1β, IL-6, IL-8, IL-10 and IL-17. Other inflammatory cells are attracted to the inflammation 
site and contribute to an inflammatory infiltrate.
We demonstrate that in patients with small bowel (SB) BD IFN-γ, IL-6 and IL-10 were 
significantly higher in patients with SB lesions than those without. It does not reflect a 
typical Th1 nor Th17 cytokine profile. Elevated IL-10 could be part of the pathogenesis 
of intestinal BD as well as a normal response on inflammation. More interestingly are 
the cytokine levels in affected tissue. We present a case of an intensively treated patient 
with high mRNA expression of IFN-gamma, TNF-alpha and IL-17A, that appear to be key 
cytokines in BD. To therapeutically target such key-enzymes can be achieved by novel 
(molecular designed) drugs.
Finally in Chapter 5 we present the results of such innovative treatment modalities.
We start with the successful use of mycophenolate sodium up front biologicals in a BD 
patient with ileo-colitis, refractory to corticosteroid- or AZA-therapy. Secondly we des-
cibe a patient with the combination of BD, psoriasis and hydradenitis suppurativa. This 
case is the first in which these three diseases were simultaneously present. In addition, 
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our case is the first BD patient reported that was effectively treated with ustekinumab. 
These reports add to few available data about the use of mycophenolates sodium and 
ustekinumab and suopply evidence to boost the armamentarium in BD.
Finally, we present data of a study of TNF-α blockage (Adalimumab). The effect of 
bi-weekly 40mg adalimumab in 9 patients with therapy refractory BD was studied 
during 6 months. The disease activity scored by the BD Current Activity Form (BDCAF) 
improved significantly in all patients from 5.4 to 2.4 (p = 0.007) within 1 month and 
improvement lasted the entire observation period so that 8 patients could either taper 
or stop concomitant therapy. Symptoms of mucocutaneous lesions, erythema nodosum 
and joint involvement decreased or completely disappeared. These data on patients 
with refractory BD treated with adalimumab provide a basis for its use in refractory 
mucocutaneous BD.
In chapter 6 we discuss the implications of our results and give our view on future 
research. We conclude that the pathophysiology of BD is complex, both genetic as envi-
ronmental factors might play a role and that translational research is be the fundament 
in the development of new molecular designed drugs, single or combination therapies 
of monoclonal antibodies that might more effectively block different inflammatory 
pathways in order to overcome escaping mechanisms.
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neDerlAnDse sAMenvATTInG
De ziekte van Behçet (BD) is een multi-factoriele (auto)inflammatoire vascilitis die vooral 
voorkomt bij mensen uit landen van de Middellandse Zee gebied en langs de voorma-
lige zijderoute naar het Verre Oosten. De symptomen bestaan uit spontane fluctuerende 
orale en genitale afteuze laesies, uveïtis en diverse huidaandoeningen. Bijkomende 
inflammatoire manifestaties kunnen zich uiten in colitis, uretritis, steriele meningitis en 
vaso-occlusie. In de vijfde eeuw voor Christus werden symptomen al door Hippocrates 
beschreven, maar pas in 1937 werd de ziekte vernoemd naar de Turkse dermatoloog 
Hulusi Behçet. In Turkije is ook de hoogste prevalentie: 70 tot 420 patiënten per 100.000 
inwoners. In Noord- Europese landen is de prevalentie rond de 1 per 100.000 inwoners 
en neemt de laatste jaren toe door de veranderende bevolkingssamenstelling. De as-
sociatie met HLA-B51 positiviteit suggereert een genetische component in de etiologie. 
BD wordt het meest gediagnosticeerd in de derde levensdecade en de ziekte lijkt vaker 
voor te komen bij mannen dan bij vrouwen.
De exacte pathofysiologie van BD moet nog worden opgehelderd, de interactie tussen 
neutrofielen en T-cellen lijkt in ieder geval een belangrijke rol te spelen. Geactiveerde 
T-cellen produceren TNF-α, wat leidt tot de productie van andere pro-inflammatoire 
cytokines zoals IL1 en IL6. Deze pro-inflammatoire cytokines stimuleren migratie en 
activatie van leukocyten, waardoor een lokale ontstekingsreactie wordt veroorzaakt.
In dit proefschrift worden translationele aspecten van BD gepresenteerd op het ge-
bied van epidemiologie, genetica, cytokines en nieuwe behandelmodaliteiten.
In hoofdstuk 2 wordt de veronderstelling dat de prevalentie van BD afneemt na mi-
gratie ter discussie gesteld. Verder wordt de ziekte presentatie van BD in een cohort in 
Rotterdam beschreven. Prevalentie van BD in de regio Rotterdam verschilt per etniciteit; 
1, 71 en 39 per 100.000 voor Nederlanders, Turken en Marokkanen, respectievelijk. Deze 
cijfers zijn gelijk aan andere cohorten uit West- Turkije en Marokko. Binnen het Erasmus 
MC cohort van 110 patiënten zijn geen significante verschillen in morbiditeit tussen de 
etnische groepen gevonden. Maar uveïtis en pustels zijn significant meer aanwezig in 
het EMC-cohort in vergelijking met Britse, Duitse, Turkse en Marokkaanse cohorten.
Bij patiënten van Turkse afkomst is er een positieve familiegeschiedenis in 12% en een 
“sibbling risk ratio”van 11-52. De erfelijkheid van BD is naar schatting tussen 20 tot 60%, 
met als sterkste genetische associatie met HLA-B51. In hoofdstuk 3 laten we zien dat 
sommige genetische varianten beschermend en andere een risico voor de ontwikkeling 
van BD kunnen zijn. In de loop der jaren zijn tal van single nucleotide polymorfismen 
(SNP's) geassocieerd met BD. Als eerste presenteerden wij dat er ook een beschermende 
associatie bij BD was, namelijk met NOD2 varianten. De eerste Genome Wide Association 
Study (GWAS) in Turkse en Japanse BD cohorten in 2010 lieten de bekende varianten in 
het HLA-B51 domein zien. Daarnaast ware er twee nieuwe signalen, de eerste in inter-
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leukine-10 (IL-10), en de tweede in IL-23 receptor IL-12 receptor beta2 (IL23R-IL12RB2) 
locus. Later zijn in GWAS studies ook relaties tussen BD en andere varianten gevonden; 
signal transducer and activator of transcription 4 (STAT4), GTPase of immune associated 
protein (GIMAP) , CCR1, STAT4 en KLRC4. Wij presenteren een GWAS met 336 BD pati-
enten en 5843 controles. De patiënten groep bestond uit West-Europeanen, Midden-
Oosten en de Turken. Het Generation R cohort, een multi-etnische geboortecohort in 
Rotterdam, werd gebruikt als controle groep. Genomic Principal Components en Linear 
Mixed Modelling zijn gebruikt voor dataverwerking. Meta-analyse werd uitgevoerd op 
geselecteerde resultaten eerder gepubliceerd. We identificeerden SNPs in het be-
kende 6p21.33 (HLA) regio, daarnaast worden twee potentiële nieuwe associaties op 
chromosomen 6 en 18 werden geïdentificeerd, maar met lage minor allel frequenties. 
Een meta-analyse laat een significante associatie met de IL12A variant rs17810546 op 
chromosoom 3 zien.
In hoofdstuk 4 stellen we dat cytokines in weefsel meer relevant zijn dan cytokines 
in serum. Tumornecrosefactor (TNF) -α speelt een centrale rol in het ontstekingsproces 
in BD, het wordt door vrijwel alle betrokken cellen geproduceerd. TNF-α activeert ver-
volgens de productie van andere cytokinen zoals interleukine (IL) -1β, IL-6, IL-8, IL-10 en 
IL-17. Andere inflammatoire cellen worden aangetrokken naar het ontstoken weefsel en 
vormen een ontstekingsinfiltraat.
We laten zien dat bij patiënten met dunne darm betrokkenheid IFN-γ, IL-6 en IL-10 
significant zijn verhoogd. Het zijn echter niet typische Th1 of Th17 profielen. Het ver-
hoogde IL-10 kan onderdeel zijn van de pathogenese van intestinale BD maar het kan 
ook een normale reactie op ontsteking zijn. Aangezien het aantal patiënten in de studie 
beperkt is, blijft het moeilijk om definitieve conclusies te trekken over de betrokken en 
het klinisch gebruik van cytokines.
Relevanter lijken de cytokine niveaus in aangetast weefsel. We presenteren een casus 
van een intensief behandelde patiënt met hoge mRNA expressie van IFN-gamma, TNF-
alfa en IL-17A.
In hoofdstuk 5 presenteren we mogelijk nieuwe behandelingen. We laten zien dat 
mycophenolate sodium een toevoeging is aan de immuunsuppressiva die bij BD ge-
bruikt kunnen worden, met name bij intestinale BD. Verder hebben wij een casus van 
een patiënt met BD in combinatie met psoriasis en hydradenitis suppurativa. Het is voor 
het eerst dat deze drie ziekten gelijktijdig worden beschreven in een patiënt. Daarnaast 
is het de eerste BD patiënt die effectief werd behandeld met ustekinumab (anti P40).
Tot slot, presenteren we een serie patienten die TNF-α blokkade (Adalimumab) heb-
ben gehad. Het effect van tweewekelijkse 40 mg adalimumab bij 9 patiënten met refrac-
taire BD therapie werd gedurende 6 maanden bestudeerd. De ziekte activiteit, gemeten 
met de BDCAF verbeterde significant bij alle patiënten van 5,4 (SD = 1,4) naar 2,4 (SD = 
1,4; p = 0,007). De verbetering was binnen 1 maand zichtbaar en was stabiel tijdens de 
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gehele observatieperiode. Symptomen van mucocutane laesies, erythema nodosum en 
gezamenlijke betrokkenheid verminderd of geheel verdwenen.
In hoofdstuk 6 bespreken we de implicaties van onze resultaten en geven onze 
visie op toekomstig onderzoek. Concluderend is de pathofysiologie van BD complex, 
zowel genetische als omgevingsfactoren spelen een rol. Translationeel onderzoek is het 
fundament voor de ontwikkeling van nieuwe moleculaire geneesmiddelen, mono- of 
combinatietherapieën van monoklonale antilichamen die effectief verschillende inflam-
matoire pathways blokkeren.
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Kiki en Serge, wat fantastisch dat jullie mijn paranimfen willen zijn. We wisten allemaal 
niet precies wat het inhield, vooral een ceremoniele functie vertelde de folder. Serge, 
nog uit Delft, samen gewoond, samen gelopen en samen een biertje gedronken. Ik hoop 
dat we dat nog lang volhouden, dat biertje dan. Kiki, samen begonnen als afwijkend in 
de collegezaal, samen onderzoek bij de immunologie. Jij wordt wel internist. Succes met 
jouw laatste loodjes.
En dan is er natuurlijk de afdeling longgeneeskunde in het SFG. Wat een fantastische 
plek om opgeleid te worden. Elke dag leer ik en elke dag lach ik.
Lieve papa en mama, zonder jullie was ik er natuurlijk niet geweest maar zonder jullie 
was ik vooral niet de persoon geworden die ik nu ben. Elk raar idee dat ik in het verleden 
had, hebben jullie gesteund, altijd stonden jullie klaar, en nog steeds. Ik hoop dat die 
onvoorwaardelijk steun ook erfelijk is en dat ik dat ook, al is het maar een beetje, heb. 
Eelco, Sandra, Lisa, Tijn, Lies, Frits, Nannie, Leon, Jasper, Ellen, Cathelijne en Vera, zonder 
het te weten hebben jullie ook bijgedragen aan dit proefschrift. Zo af en toe vragen hoe 
het ging, “ben je eigenlijk nog aan het promoveren?“ Het stimuleerde elke keer weer.
Als laatste, Floor, Joris en Rosa, voor jullie geldt stuk voor stuk;
“ik draag je hart met me mee (ik draag het in mijn hart)
ik heb het altijd bij me (waar ik ga, daar ga jij en alles wat ik doe doe ik om jou)
Ik vrees mijn lot niet (want jij bent mijn lot)
ik wil de wereld niet (want mooi ben jij, mijn wereld, mijn ware)
en jij bent het, jij bent wat de maan altijd heeft bedoeld
en wat de zon steeds weer zal zingen dat ben jij”
 E.E. Cummings
Dan wil ik eindigen met de woorden waarmee elke voordracht eindigt; More research is 
needed, heel graag!
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